Skip to main content
Psychedex
Sources
34
3 strong · 17 moderate · 14 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
118
96verified8partial13inconclusive1not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 12, 2026 · pipeline-v5
Values approved
95/95 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold50 mg50 mgmedium
Low100–325 mg100–325 mgmedium
Common325–500 mg325–500 mgmedium
Strong500–750 mg500–750 mgmedium
Heavy750+ mg750+ mgmedium
Editorial

Seed DB values carried forward. Therapeutic dose 250-350 mg confirmed by FDA label and Zacny et al. controlled study. Recreational tiers are community-derived. CYP2C19 poor metabolizers experience ~4-fold higher exposure — effectively shifting 1-2 tiers higher.

Reasoning

Seed DB values carried forward. Therapeutic dose 250-350 mg confirmed by FDA label and Zacny et al. controlled study. Recreational tiers are community-derived. CYP2C19 poor metabolizers experience ~4-fold higher exposure — effectively shifting 1-2 tiers higher.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
After effectstrace1–12 hours1–12 hoursmedium
Editorial

From seed data; wide range reflects meprobamate t½ ~10h contribution and dose/metabolizer status variability.

Reasoning

From seed data; wide range reflects meprobamate t½ ~10h contribution and dose/metabolizer status variability.

Evidence basis: community_consensus_large

Onsettrace15–60 minutes15–60 minutesmedium
Editorial

From seed data; consistent with Tmax 1.5-2h (FDA label, Dalén et al. 1996).

Reasoning

From seed data; consistent with Tmax 1.5-2h (FDA label, Dalén et al. 1996).

Evidence basis: community_consensus_large

Come uptrace15–45 minutes15–45 minuteslow
Editorial

Inferred from Tmax 1.5-2h; come-up expected to bridge onset awareness to approaching peak. No direct published data.

Reasoning

Inferred from Tmax 1.5-2h; come-up expected to bridge onset awareness to approaching peak. No direct published data.

Evidence basis: community_consensus_large

Peaktrace2–5 hours2–5 hoursmedium
Editorial

From seed data; consistent with carisoprodol t½ ~2h and Tmax 1.5-2h creating a peak window of several hours.

Reasoning

From seed data; consistent with carisoprodol t½ ~2h and Tmax 1.5-2h creating a peak window of several hours.

Evidence basis: community_consensus_large

Offsettrace1–3 hours1–3 hourslow
Editorial

Inferred from carisoprodol t½ ~2h; as parent compound declines, meprobamate sustains residual effects during offset. No direct published data for subjective offset duration.

Reasoning

Inferred from carisoprodol t½ ~2h; as parent compound declines, meprobamate sustains residual effects during offset. No direct published data for subjective offset duration.

Evidence basis: community_consensus_large

Totaltrace4–8 hours4–8 hourslow
Editorial

Inferred from combined carisoprodol (t½ ~2h) and meprobamate (t½ ~10h) PK. Subjective total experience encompasses onset through offset. No direct published data.

Reasoning

Inferred from combined carisoprodol (t½ ~2h) and meprobamate (t½ ~10h) PK. Subjective total experience encompasses onset through offset. No direct published data.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutehighhighhigh
Chronichighhighhigh
Organs AffectedCNS, hepatic, renalCNS, hepatic, renalhigh
Editorial

Forensic postmortem data (McIntyre et al. 2012, Høiseth et al. 2007) document fatal concentrations and toxicity index. Polydrug overdose HR 1.84 confirmed in two independent cohort studies (Li et al. 2020, Khan et al. 2022). CYP2C19 PM genotype investigated in fatal intoxications (Høiseth et al. 2012).

Reasoning

Forensic postmortem data (McIntyre et al. 2012, Høiseth et al. 2007) document fatal concentrations and toxicity index. Polydrug overdose HR 1.84 confirmed in two independent cohort studies (Li et al. 2020, Khan et al. 2022). CYP2C19 PM genotype investigated in fatal intoxications (Høiseth et al. 2012).

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalhighhighhigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationhighhighhigh
Editorial

Multiple case series document dependence (Rust 1993, Littrell 1993, Reeves 1997, Vo 2017). Norwegian epidemiological data (Bramness 2007) confirm population-level high-use patterns. Mouse model (Gatch 2012) confirmed physical dependence via precipitated withdrawal.

Reasoning

Multiple case series document dependence (Rust 1993, Littrell 1993, Reeves 1997, Vo 2017). Norwegian epidemiological data (Bramness 2007) confirm population-level high-use patterns. Mouse model (Gatch 2012) confirmed physical dependence via precipitated withdrawal.

Evidence basis: published_case_series

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitylife_threateninglife_threateningmedium
Symptomsanxiety, insomnia, restlessness, craving, headache, seizures, hallucinations, delirium, delusionsanxiety, insomnia, restlessness, craving, headache, seizures, hallucinations, delirium, delusionsmedium
FatalYesYesmedium
Medical SupervisionRequiredRequiredmedium
Editorial

Withdrawal onset inferred from meprobamate t½ (~10h); expected within 24-48 hours. Seizures, hallucinations, and delirium documented in case reports (Vo et al. 2017). Clinically similar to barbiturate withdrawal — potentially life-threatening. Duration not precisely characterized in literature; estimated days to weeks based on barbiturate/benzodiazepine withdrawal analogy.

Reasoning

Withdrawal onset inferred from meprobamate t½ (~10h); expected within 24-48 hours. Seizures, hallucinations, and delirium documented in case reports (Vo et al. 2017). Clinically similar to barbiturate withdrawal — potentially life-threatening. Duration not precisely characterized in literature; estimated days to weeks based on barbiturate/benzodiazepine withdrawal analogy.

Evidence basis: published_case_series

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatelow
Half-life7 days7 dayslow
Full Reset30 days30 dayslow
Cross-tolerancesbenzodiazepines, barbiturates, alcoholbenzodiazepines, barbiturates, alcohollow
Editorial

Mouse model (Gatch et al. 2012) established tolerance development and physical dependence. Kinetics inferred from GABA-A downregulation parallels with barbiturates/benzodiazepines. No human tolerance half-life data available.

Reasoning

Mouse model (Gatch et al. 2012) established tolerance development and physical dependence. Kinetics inferred from GABA-A downregulation parallels with barbiturates/benzodiazepines. No human tolerance half-life data available.

Evidence basis: animal_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
neurological Myasthenia gravistracerelativerelativelow
Editorial

Class inference from GABA-A PAM/direct agonist contraindications. No substance-specific data for carisoprodol in myasthenia gravis.

Reasoning

Class inference from GABA-A PAM/direct agonist contraindications. No substance-specific data for carisoprodol in myasthenia gravis.

metabolic CYP2C19 poor metabolizer statustraceabsoluteabsolutehigh
Editorial

Forensic case series (Høiseth et al. 2012) confirmed CYP2C19 PM genotype in fatal carisoprodol intoxications; ~4-fold exposure increase documented in PK studies (Dalén et al. 1996).

Reasoning

Forensic case series (Høiseth et al. 2012) confirmed CYP2C19 PM genotype in fatal carisoprodol intoxications; ~4-fold exposure increase documented in PK studies (Dalén et al. 1996).

hepatic Severe hepatic impairmenttracerelativerelativelow
Editorial

Class inference from GABA-A direct agonist contraindications. Hepatic metabolism is primary elimination pathway (CYP2C19); impairment would alter drug exposure. Not substance-specific data.

Reasoning

Class inference from GABA-A direct agonist contraindications. Hepatic metabolism is primary elimination pathway (CYP2C19); impairment would alter drug exposure. Not substance-specific data.

respiratory Concurrent opioid usetraceabsoluteabsolutehigh
Editorial

Li et al. 2020 cohort study demonstrated HR 1.84 for opioid overdose with concomitant carisoprodol; confirmed independently by Khan et al. 2022.

Reasoning

Li et al. 2020 cohort study demonstrated HR 1.84 for opioid overdose with concomitant carisoprodol; confirmed independently by Khan et al. 2022.

immunological Meprobamate or carisoprodol hypersensitivitytraceabsoluteabsolutehigh
Editorial

FDA prescribing information lists hypersensitivity as absolute contraindication; metabolic conversion ensures cross-exposure.

Reasoning

FDA prescribing information lists hypersensitivity as absolute contraindication; metabolic conversion ensures cross-exposure.

respiratory Concurrent benzodiazepine usetracerelativerelativehigh
Editorial

Horsfall & Sprague 2017 documented synergistic respiratory depression and dopamine release via converging GABA-A and μ-opioid pathways in the 'Holy Trinity' combination.

Reasoning

Horsfall & Sprague 2017 documented synergistic respiratory depression and dopamine release via converging GABA-A and μ-opioid pathways in the 'Holy Trinity' combination.

other Concurrent alcohol usetracerelativerelativehigh
Editorial

Forensic literature (McIntyre et al. 2012) documents carisoprodol contributing to death at therapeutic concentrations when combined with other CNS depressants including alcohol.

Reasoning

Forensic literature (McIntyre et al. 2012) documents carisoprodol contributing to death at therapeutic concentrations when combined with other CNS depressants including alcohol.

other Treatment duration exceeding 2-3 weekstracerelativerelativehigh
Editorial

FDA prescribing information limits recommended duration; Bramness et al. 2007 documented high-use patterns in 15% of Norwegian patients.

Reasoning

FDA prescribing information limits recommended duration; Bramness et al. 2007 documented high-use patterns in 15% of Norwegian patients.

age Elderly patients (>65 years)tracerelativerelativemedium
Editorial

Beers Criteria listing web-retrieved; not confirmed via primary published source. Work-notes flag as safety_data_unverified.

Reasoning

Beers Criteria listing web-retrieved; not confirmed via primary published source. Work-notes flag as safety_data_unverified.

age Pediatric patients (<16 years)tracerelativerelativehigh
Editorial

FDA prescribing information explicitly notes lack of established safety/efficacy in pediatric population.

Reasoning

FDA prescribing information explicitly notes lack of established safety/efficacy in pediatric population.

pregnancy breastfeeding Pregnancytracerelativerelativemedium
Editorial

FDA prescribing information acknowledges decades of use without identified major risk but lacks formal safety data.

Reasoning

FDA prescribing information acknowledges decades of use without identified major risk but lacks formal safety data.

neurological Concurrent serotonergic agentstracerelativerelativemedium
Editorial

Bramness et al. 2005 (4 cases meeting 3 serotonin syndrome criteria sets) and O'Flynn et al. 2025 case report. Mechanism unknown — flagged as safety_data_unverified.

Reasoning

Bramness et al. 2005 (4 cases meeting 3 serotonin syndrome criteria sets) and O'Flynn et al. 2025 case report. Mechanism unknown — flagged as safety_data_unverified.

metabolic CYP2C19 inhibitor co-administrationtracerelativerelativehigh
Editorial

FDA prescribing information and Pratt et al. 2012 document CYP2C19-mediated interaction; inhibitors mimic the ~4-fold exposure increase seen in genetic PMs.

Reasoning

FDA prescribing information and Pratt et al. 2012 document CYP2C19-mediated interaction; inhibitors mimic the ~4-fold exposure increase seen in genetic PMs.

respiratory Respiratory compromisetracerelativerelativelow
Editorial

Class inference from GABA-A PAM/direct agonist pharmacology. Direct gating produces barbiturate-like respiratory depression profile. Not substance-specific data.

Reasoning

Class inference from GABA-A PAM/direct agonist pharmacology. Direct gating produces barbiturate-like respiratory depression profile. Not substance-specific data.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace900–3600 sec(i=0.20)900–3600 sec(i=0.20)medium
Editorial

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Reasoning

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Evidence basis: community_consensus_large

Come uptrace900–2700 sec(i=0.50)900–2700 sec(i=0.50)medium
Editorial

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Reasoning

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Evidence basis: community_consensus_large

Peaktrace7200–18000 sec(i=1.00)7200–18000 sec(i=1.00)medium
Editorial

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Reasoning

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Evidence basis: community_consensus_large

Resolutiontrace3600–10800 sec(i=0.50)3600–10800 sec(i=0.50)medium
Editorial

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Reasoning

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Evidence basis: community_consensus_large

Afterglowtrace3600–43200 sec(i=0.20)3600–43200 sec(i=0.20)medium
Editorial

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Reasoning

Onset and peak from seed data, consistent with published PK (Tmax 1.5-2h, t½ ~2h carisoprodol, ~10h meprobamate). Come-up and resolution inferred from PK parameters. Afterglow wide range reflects meprobamate contribution and metabolizer variability. Driving advisory from work-notes based on Zacny et al. controlled study demonstrating psychomotor deficits despite minimal subjective awareness.

Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace
medium

Minimal perceptible effects emerge as a subtle softening of muscle tension without significant sedation or cognitive change. Anxiety suppression may be faintly detectable but falls below reliable awareness for most individuals. Physical effects are limited to slight muscle relaxation. Psychomotor function remains largely intact on objective testing. No meaningful body high or sedation. This range serves as an entry point for assessing individual sensitivity — particularly relevant given CYP2C19 metabolizer variability, which can produce up to 4-fold differences in exposure at identical doses.

Editorial

Work-notes outline for threshold tier. Minimal effects consistent with sub-therapeutic dosing below the FDA-approved 250mg minimum. CYP2C19 variability note from PK literature (Dalén et al. 1996).

Reasoning

Work-notes outline for threshold tier. Minimal effects consistent with sub-therapeutic dosing below the FDA-approved 250mg minimum. CYP2C19 variability note from PK literature (Dalén et al. 1996).

Evidence basis: community_consensus_large

lighttrace
medium

Noticeable muscle relaxation and mild sedation develop. Anxiety suppression becomes apparent as a gentle quieting of baseline tension. The subjective state is calm but not dramatically altered. Psychomotor impairment may be present on objective testing despite minimal subjective awareness — a characteristic dissociation documented even at the lower therapeutic dose. Motor control impairment is subtle but measurable. Mild dizziness possible. This range overlaps with the lower therapeutic dose (250 mg). Functional impairment is easily underestimated. Duration of effects: 4-6 hours including residual meprobamate contribution.

Editorial

Work-notes outline; Zacny et al. controlled study documented measurable psychomotor deficits at 350mg despite minimal subjective awareness. Overlaps therapeutic range per FDA label.

Reasoning

Work-notes outline; Zacny et al. controlled study documented measurable psychomotor deficits at 350mg despite minimal subjective awareness. Overlaps therapeutic range per FDA label.

Evidence basis: community_consensus_large

commontrace
medium

Pronounced muscle relaxation, moderate sedation, and clear anxiolysis define this range. Thought deceleration becomes evident — cognitive processing slows perceptibly. Delusions of sobriety are characteristic: users feel less impaired than objective testing demonstrates. Physical effects include noticeable motor control impairment, bodily heaviness, and dizziness. Tactile euphoria may emerge in some individuals. Pain suppression is moderate. Sedation dominates the physical profile without approaching incapacitation. This encompasses the standard therapeutic range (325-500 mg). Driving and machinery operation are objectively impaired even when the user feels capable. Cognitive euphoria reported by some but not confirmed in controlled settings.

Editorial

Work-notes outline; encompasses FDA therapeutic range. Zacny et al. documented psychomotor impairment and dissociation from subjective awareness. Delusions of sobriety confirmed in controlled study.

Reasoning

Work-notes outline; encompasses FDA therapeutic range. Zacny et al. documented psychomotor impairment and dissociation from subjective awareness. Delusions of sobriety confirmed in controlled study.

Evidence basis: community_consensus_large

strongtrace
medium

Heavy sedation dominates with significant motor control impairment. Amnesia becomes possible at this range. Analysis suppression and language suppression are pronounced — coherent conversation becomes effortful. Disinhibition increases behavioral unpredictability. Physical effects include marked bodily heaviness, pronounced dizziness, and potential for respiratory depression that begins increasing meaningfully. Tactile euphoria reported in abuse contexts. Coordination severely compromised. Driving and machinery operation are objectively hazardous. Compulsive redosing urge may emerge. Risk of falls and accidental injury is substantial. CYP2C19 poor metabolizers may reach this pharmacological intensity at common-tier doses.

Editorial

Work-notes outline; supratherapeutic range. Zacny et al. 700mg dose produced significant sedation-type VAS elevations and psychomotor impairment. Amnesia and euphoria documented in case reports and abuse literature.

Reasoning

Work-notes outline; supratherapeutic range. Zacny et al. 700mg dose produced significant sedation-type VAS elevations and psychomotor impairment. Amnesia and euphoria documented in case reports and abuse literature.

Evidence basis: community_consensus_large

heavytrace
medium

Severe sedation approaching stupor. Confusion, spatial disorientation, and delirium documented at this level. Amnesia is likely — memory formation substantially impaired. Delusions of sobriety persist paradoxically even at this intensity, compounding danger. Respiratory depression risk is high, particularly in polydrug contexts or CYP2C19 poor metabolizers. Fatal blood concentrations (>15 mg/L) become achievable, especially with repeated dosing where meprobamate accumulates. Motor control impairment is profound — falls and aspiration risk are significant. This dose range approaches documented fatal concentrations. Emergency medical risk is substantial. CYP2C19 poor metabolizers effectively experience this tier at standard strong-tier doses due to ~4-fold exposure increase.

Editorial

Work-notes outline; forensic literature (McIntyre et al. 2012, Høiseth et al. 2007) documents fatal concentrations. ACMD report lists confusion, disorientation, delirium at high doses. Respiratory depression as primary lethal mechanism from multiple sources.

Reasoning

Work-notes outline; forensic literature (McIntyre et al. 2012, Høiseth et al. 2007) documents fatal concentrations. ACMD report lists confusion, disorientation, delirium at high doses. Respiratory depression as primary lethal mechanism from multiple sources.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

3 strong · 17 moderate · 14 weak
  1. [1]
    moderate
    Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors
    Kumar M, Gonzalez LA, Dillon GH · 2015 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2015.04.007pubmed 2589676711 claims checked7 verified3 partial1 inconclusive
  2. [2]
    moderate
    THE HISTORY, CHEMISTRY, AND PHARMACOLOGY OF CARISOPRODOL
    Berger F, Kletzkin M, Ludwig B, Margolin S · 1960 · Annals of the New York Academy of Sciences
    doi.org/10.1111/j.1749-6632.1960.tb42792.x7 claims checked6 verified1 inconclusive
  3. [3]
    weak
    ACMD Report: A Review of the Evidence on the Use and Harms of Carisoprodol
    Advisory Council on the Misuse of Drugs (ACMD) · 2025
    linkno claims checked
  4. [4]
    moderate
    Characterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers
    Zacny JP, Paice JA, Coalson DW · 2011 · Pharmacology Biochemistry and Behavior
    doi.org/10.1016/j.pbb.2011.08.011pubmed 218847208 claims checked7 verified1 inconclusive
  5. [5]
    weak
    Postmortem carisoprodol and meprobamate concentrations in blood and liver: lack of significant redistribution
    McIntyre IM, Sherrard J, Lucas J · 2012 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bks011pubmed 224178334 claims checked4 verified
  6. [6]
    moderate
    Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study
    Li Y, Delcher C, Wei YJ, Reisfield GM, Brown JD, Tighe P, Winterstein AG · 2020 · Clinical Pharmacology and Therapeutics
    doi.org/10.1002/cpt.1807pubmed 320229064 claims checked4 verified
  7. [7]
    weak
    Carisoprodol intoxications and serotonergic features
    Bramness JG, Morland J, Sorlid HK, Rudberg N, Jacobsen D · 2005 · Clinical Toxicology
    pubmed 157324457 claims checked7 verified
  8. [8]
    strong
    Muscle relaxants for non-specific low-back pain
    van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM · 2003 · Cochrane Database of Systematic Reviews
    doi.org/10.1002/14651858.cd004252pubmed 128045072 claims checked1 verified1 partial
  9. [9]
    moderate
    Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors
    Kumar M, Dillon GH · 2016 · European Journal of Pharmacology
    doi.org/10.1016/j.ejphar.2016.02.031pubmed 268729876 claims checked4 verified2 inconclusive
  10. [10]
    moderate
    Formation of meprobamate from carisoprodol is catalysed by CYP2C19
    Dalen P, Alvan G, Wakelkamp M, Olsen H · 1996 · Pharmacogenetics
    pubmed 89464708 claims checked5 verified3 inconclusive
  11. [11]
    weak
    Severe Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose
    Vo KT, Horng H, Smollin CG, Benowitz NL · 2017 · Journal of Emergency Medicine
    doi.org/10.1016/j.jemermed.2016.11.015pubmed 279796426 claims checked6 verified
  12. [12]
    weak
    CYP2C19 genetics in fatal carisoprodol intoxications
    Hoiseth G, Majid U, Morland J, Bramness JG, Molden E · 2012 · European Journal of Clinical Pharmacology
    doi.org/10.1007/s00228-012-1278-6pubmed 225273455 claims checked2 verified1 partial2 inconclusive
  13. [13]
    weak
    Carisoprodol as a drug of abuse
    Rust GS, Hatch R, Gums JG · 1993 · Archives of Family Medicine
    pubmed 81309232 claims checked2 verified
  14. [14]
    weak
    Meprobamate dependence secondary to carisoprodol (Soma) use
    Littrell RA, Sage T, Miller W · 1993 · American Journal of Drug and Alcohol Abuse
    pubmed 84388282 claims checked2 verified
  15. [15]
    weak
    Carisoprodol: A drug of continuing abuse
    Reeves RR, Pinkofsky HB, Carter OS · 1997 · Journal of the American Osteopathic Association
    pubmed 94391442 claims checked2 verified
  16. [16]
    moderate
    Carisoprodol use and abuse in Norway: A pharmacoepidemiological study
    Bramness JG, Furu K, Engeland A, Skurtveit S · 2007 · British Journal of Clinical Pharmacology
    doi.org/10.1111/j.1365-2125.2007.02847.x3 claims checked1 verified2 partial
  17. [17]
    moderate
    The effect of scheduling and withdrawal of carisoprodol on prevalence of intoxications with the drug
    Hoiseth G, Karinen R, Sorlid HK, Bramness JG · 2009 · Basic and Clinical Pharmacology and Toxicology
    doi.org/10.1111/j.1742-7843.2009.00459.xpubmed 196638223 claims checked1 verified1 inconclusive1 not supported
  18. [18]
    weak
    Schedules of Controlled Substances: Placement of Carisoprodol Into Schedule IV
    US Drug Enforcement Administration · 2011
    linkno claims checked
  19. [19]
    moderate
    Role of drug testing as an early warning programme: the experience of the Republic of Korea
    Chung H · 2005 · Bulletin on Narcotics
    pubmed 213380241 claim checked1 verified
  20. [20]
    moderate
    The Pharmacology and Toxicology of the 'Holy Trinity'
    Horsfall JT, Sprague JE · 2017 · Basic & Clinical Pharmacology & Toxicology
    doi.org/10.1111/bcpt.12655pubmed 275501525 claims checked5 verified
  21. [21]
    moderate
    Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies
    Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ · 2009 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.109.151142pubmed 192440961 claim checked1 inconclusive
  22. [22]
    moderate
    A Single Amino Acid Residue at Transmembrane Domain 4 of the Alpha Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors
    Kumar M, Kumar M, Freund JM, Dillon GH · 2017 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.117.242156pubmed 286422323 claims checked3 verified
  23. [23]
    weak
    Carisoprodol poisoning with serotonin toxicity
    O'Flynn CS, Singh S, Tan G · 2025 · BMJ Case Reports
    doi.org/10.1136/bcr-2025-269513pubmed 413604966 claims checked6 verified
  24. [24]
    weak
    DailyMed: CARISOPRODOL Prescribing Information
    US FDA / DailyMed · 2024
    linkno claims checked
  25. [25]
    moderate
    Carisoprodol Therapy and CYP2C19 Genotype
    Pratt VM, Scott SA, Pirmohamed M, et al. · 2012 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bku002pubmed 285203828 claims checked8 verified
  26. [26]
    moderate
    Carisoprodol tolerance and precipitated withdrawal
    Gatch MB, Nguyen JD, Carbonaro T, Forster MJ · 2012 · Drug and Alcohol Dependence
    doi.org/10.1016/j.drugalcdep.2011.10.010pubmed 220550102 claims checked2 verified
  27. [27]
    strong
    Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm
    Ralph L, Look M, Wheeler W, Sacks H · 2008 · Current Medical Research and Opinion
    pubmed 181945911 claim checked1 verified
  28. [28]
    strong
    Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review
    Chou R, Peterson K, Helfand M · 2004 · Journal of Pain and Symptom Management
    doi.org/10.1016/j.jpainsymman.2004.05.002pubmed 152761952 claims checked1 verified1 partial
  29. [29]
    moderate
    Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003
    Hoiseth G, Bramness JG, Christophersen AS, Morland J · 2007 · International Journal of Legal Medicine
    pubmed 171151702 claims checked2 verified
  30. [30]
    moderate
    Comparative Risk of Opioid Overdose With Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants
    Khan NF, Bykov K, Barnett ML, Glynn RJ, Vine SM, Gagne JJ · 2022 · Neurology
    doi.org/10.1212/wnl.0000000000200904pubmed 358355612 claims checked1 verified1 inconclusive
  31. [31]
    weak
    A multi-drug intoxication fatality involving Xyrem (GHB)
    Akins BE, Miranda E, Lacy JM, Logan BK · 2009 · Journal of Forensic Sciences
    doi.org/10.1111/j.1556-4029.2008.00965.xpubmed 191874562 claims checked2 verified
  32. [32]
    weak
    Carisoprodol: an underrecognized drug of abuse in north India
    Nebhinani N, Aggarwal M, Mattoo SK, Basu D · 2013 · General Hospital Psychiatry
    doi.org/10.1016/j.genhosppsych.2012.07.011pubmed 229594191 claim checked1 verified
  33. [33]
    weak
    Multidrug toxicity involving sumatriptan
    Knittel JL, Vorce SP, Levine B, Hughes RL, Bosy TZ · 2015 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bku120pubmed 253245262 claims checked2 verified
  34. [34]
    moderate
    Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone
    Toth PP, Urtis J · 2004 · Clinical Therapeutics
    pubmed 15530999no claims checked
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary12 claims8verified3partial1inconclusive
partialUnlike benzodiazepines, which act solely as positive allosteric modulators, carisoprodol functions as both a positive allosteric modulator and a direct gating agonist at GABA-A receptors, producing sedation, muscle relaxation, and dose-dependent psychomotor impairment over a 4–6 hour effective window.[1]model confidence 75%
Partial

The abstract directly confirms carisoprodol acts as both a positive allosteric modulator and a direct gating agonist at GABA-A receptors. However, the '4–6 hour effective window' is a specific duration not mentioned in the abstract, and the benzodiazepine comparison is not addressed.

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs; subunit-dependent effects

checked by claude-sonnet-4-6 · May 12, 2026

verifiedLudwig at Wallace Laboratories in the early 1950s as a structural modification of meprobamate, intended to deliver superior muscle relaxation with reduced abuse liability[2]model confidence 72%
Verified

The abstract confirms this is the primary historical source describing the discovery by developers at Wallace Laboratories. The paper's scope covers discovery, chemistry, and pharmacology, making it the appropriate citation for this historical claim about origins and design intent.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

partialSystematic reviews confirm fair evidence of efficacy for acute low back pain, but adverse CNS effects are significantly more prevalent than with placebo.[8]model confidence 82%
Partial

The abstract confirms adverse events are significantly more prevalent than with placebo, and confirms efficacy for acute LBP. However, the abstract states 'strong evidence' — the claim's 'fair evidence' is a materially different quality-of-evidence designation.

Strong evidence that muscle relaxants are more effective than placebo for acute LBP short-term pain relief; adverse events significantly more prevalent with muscle relaxants.

checked by claude-sonnet-4-6 · May 12, 2026

partialCarisoprodol's dual GABA-A action — allosteric potentiation (highest at α1-containing receptors) and direct channel gating (with greater-than-GABA efficacy at extrasynaptic α1β3δ and α4β3δ receptors) — produces a barbiturate-like pharmacological profile[1]model confidence 78%
Partial

The abstract confirms direct gating with greater efficacy than GABA at extrasynaptic receptors. However, the claim states allosteric potentiation is highest at α1-containing receptors, while the abstract states 'beta2 confers highest allosteric modulation' — the β subunit, not the α subunit, is the key determinant here. This is a specific factual discrepancy.

beta1 confers highest direct activation; beta2 confers highest allosteric modulation; alpha3 shows reduced direct gating; extrasynaptic receptors show greater efficacy for carisoprodol than GABA.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCYP2C19 N-dealkylation converts carisoprodol (t½ ~2 hours) to meprobamate (t½ ~10 hours), which itself directly gates and allosterically modulates GABA-A receptors; meprobamate accumulation during repeated dosing contributes substantially to both therapeutic and abuse-related effects[9]model confidence 80%
Verified

This citation is for the meprobamate GABA-A pharmacology. The abstract directly confirms meprobamate directly gates and allosterically modulates GABA-A receptors with barbiturate-like activity. The half-life figures and CYP2C19 are addressed by co-citation [17]; this citation appropriately covers the meprobamate pharmacodynamic portion.

Meprobamate (primary metabolite of carisoprodol) modulates GABAA receptors with barbiturate-like activity... direct gating present with all alpha subunits.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCYP2C19 N-dealkylation converts carisoprodol (t½ ~2 hours) to meprobamate (t½ ~10 hours), which itself directly gates and allosterically modulates GABA-A receptors; meprobamate accumulation during repeated dosing contributes substantially to both therapeutic and abuse-related effects[10]model confidence 80%
Verified

This citation covers the CYP2C19 N-dealkylation mechanism. The abstract confirms N-dealkylation is catalyzed by CYP2C19. The specific half-life figures are not in the abstract but the metabolic pathway and PK difference between PMs and EMs are confirmed.

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe subjective profile is dominated by sedation, anxiolysis, muscle relaxation, and motor impairment, with euphoria reported primarily in abuse contexts; a controlled human study found that even the therapeutic dose (350 mg) produced measurable psychomotor deficits despite minimal subjective awareness of impairment.[4]model confidence 90%
Verified

The abstract directly confirms: 700mg produced sedation and psychomotor impairment; 350mg produced minimal subjective effects but still caused psychomotor impairment. The dissociation between subjective and objective impairment at the therapeutic dose is explicitly described.

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedBlood concentrations exceeding 15 mg/L are potentially fatal in isolation, and the compound can contribute to death at therapeutic concentrations when combined with other CNS depressants[5]model confidence 95%
Verified

The abstract directly states both key claims: blood carisoprodol >15 mg/L may be considered potentially fatal, and carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs.

Blood carisoprodol >15 mg/L and liver >50 mg/kg may be considered excessive and potentially fatal... Carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedConcomitant opioid use increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34–2.54)[6]model confidence 97%
Verified

The abstract directly reports the adjusted HR 1.84 (95% CI 1.34–2.54) for opioid overdose with carisoprodol co-use. The '84% increase' is a correct interpretation of HR 1.84.

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPhysical and psychological dependence develop rapidly; withdrawal after prolonged use can produce seizures, hallucinations, and delirium[11]model confidence 78%
Verified

The abstract confirms severe withdrawal after long-term use with barbiturate-like properties and management with benzodiazepines and antipsychotics. Antipsychotic management strongly implies hallucinations/delirium; barbiturate-like withdrawal is associated with seizures. The specific symptoms aren't enumerated in the abstract text, but the case supports these.

Case of severe carisoprodol withdrawal after 14-year addiction; barbiturate-like GABA-A properties; withdrawal managed with benzodiazepines or antipsychotic agents.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveCYP2C19 poor metabolizers — 15–20% of Asian populations — face approximately four-fold higher carisoprodol exposure at standard doses, constituting a pharmacogenomic vulnerability to toxicity at otherwise routine prescriptions[12]model confidence 70%
Inconclusive

The abstract confirms CYP2C19 mutations were investigated in fatal carisoprodol intoxications and that conversion is almost solely mediated by CYP2C19. However, neither the 15–20% Asian population prevalence nor the four-fold exposure increase are mentioned in this abstract — those figures come from other studies (e.g., citation [15]).

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAn unresolved serotonergic mechanism, documented via case reports meeting serotonin syndrome criteria, adds a further layer of clinical complexity.[7]model confidence 92%
Verified

The abstract directly describes four cases of carisoprodol intoxication meeting three different serotonin syndrome criteria sets, with central serotonin excess suggested as a mechanism distinct from expected GABAergic effects — consistent with the claim of an unresolved serotonergic mechanism adding clinical complexity.

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects.

checked by claude-sonnet-4-6 · May 12, 2026

history10 claims7verified1partial1inconclusive1not supported
verifiedThe structural modification was minimal but pharmacologically significant: substitution of one hydrogen on a carbamyl nitrogen with an isopropyl group, yielding a propanediol dicarbamate with the intended advantages of superior muscle relaxation, reduced abuse potential, and greater safety in overdose.[2]model confidence 70%
Verified

This is the primary historical paper by the developers at Wallace Laboratories covering the chemistry of carisoprodol. The abstract confirms it covers the chemistry and pharmacology by the developers, making it the appropriate citation for structural chemistry and design intention claims. The specific structural details would be in the full paper.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedRust et al. documented carisoprodol abuse and fatality cases in 1993, with NIDA data indicating overdose was more common than previously suspected[13]model confidence 85%
Verified

The abstract confirms: a group abusing carisoprodol under false pretenses, a prior fatality linked to abuse, and NIDA data suggesting overdose was more common than suspected. The content matches, though author name and year are not verifiable from the abstract text alone.

Small group discovered colluding to obtain carisoprodol under false pretenses for abuse; prior fatality linked to carisoprodol abuse; NIDA data suggesting overdose more common than suspected.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedLittrell et al. described meprobamate dependence developing secondarily from chronic carisoprodol use, establishing that the metabolite — not merely the parent compound — mediated physical dependence[14]model confidence 90%
Verified

The abstract directly states the paper documents meprobamate dependence arising from carisoprodol use, which directly supports the claim that the metabolite mediates physical dependence.

Documents meprobamate dependence arising from carisoprodol use.

checked by claude-sonnet-4-6 · May 12, 2026

partialBy the early 2000s, pharmacoepidemiological data from Norway revealed that 15% of carisoprodol patients received 75 or more defined daily doses per year, a utilization pattern consistent with tolerance and dependence.[16]model confidence 80%
Partial

The abstract confirms Norwegian pharmacoepidemiological data showing a heavy-use pattern, but reports '32% received more than 15 DDDs' — not the '15% received ≥75 DDDs' stated in the claim. These are materially different statistics.

53,889 Norwegian women (2.4%) and 29,824 men (1.3%) received carisoprodol in 2004; 32% received more than 15 DDDs.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedNorway reclassified carisoprodol to its highest scheduling level on 1 August 2007 and withdrew it from the market entirely on 1 May 2008. Post-withdrawal surveillance confirmed dramatic reductions in DUI cases, forensic autopsies, and poison control contacts involving the drug.[17]model confidence 97%
Verified

The abstract directly confirms: highest scheduling Aug 2007, market withdrawal May 2008, 1261 DUI cases and 194 forensic autopsies and 1180 poison control contacts from 2004–2008, and that rescheduling and market withdrawal significantly reduced intoxications.

Norway reclassified carisoprodol to highest scheduling Aug 2007, withdrawn from market May 2008... Rescheduling and market withdrawal significantly reduced intoxications.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedSouth Korea implemented controls following documented abuse and fatalities.[19]model confidence 93%
Verified

The abstract directly confirms that South Korea accumulated fatality data on carisoprodol that led to the introduction of controls, with drug testing used as an early warning system.

South Korea used urine and postmortem drug testing as early warning system for non-controlled drugs including carisoprodol; accumulated fatality data led to introduction of controls.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedLudwig at Wallace Laboratories, a division of Carter Products (later Carter-Wallace), in the early 1950s[2]model confidence 72%
Verified

The abstract confirms this is the primary historical source from the developers at Wallace Laboratories, which covers the discovery. The specific corporate parentage (Carter Products/Carter-Wallace) would be in the full paper.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe landmark comprehensive review — 'The History, Chemistry, and Pharmacology of Carisoprodol' by Berger, Kletzkin, Ludwig, and Margolin — was published in 1960 in the Annals of the New York Academy of Sciences.[2]model confidence 60%
Inconclusive

The abstract confirms the paper describes discovery, chemistry, and pharmacology by developers at Wallace Laboratories, and the title matches. However, the specific authors (Berger, Kletzkin, Ludwig, Margolin), publication year (1960), and journal (Annals of the New York Academy of Sciences) cannot be verified from the abstract text provided.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedReeves et al. published a case series in 1997 documenting a pattern of escalating carisoprodol abuse[15]model confidence 85%
Verified

The abstract confirms three cases demonstrating patterns of abuse, consistent with a case series documenting abuse patterns. Author name and year are not verifiable from the abstract alone, but the content matches.

Carisoprodol (Soma) is a noncontrolled skeletal-muscle relaxant whose active metabolite is meprobamate; three cases demonstrating patterns of abuse.

checked by claude-sonnet-4-6 · May 12, 2026

not supportedThe European Union withdrew marketing authorization for carisoprodol in 2008.[17]model confidence 85%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

The abstract covers Norway's market withdrawal in May 2008 specifically. Norway is not an EU member state, and the abstract makes no mention of EU-wide marketing authorization withdrawal. The claim conflates Norway's national withdrawal with an EU action.

Norway reclassified carisoprodol to highest scheduling Aug 2007, withdrawn from market May 2008.

checked by claude-sonnet-4-6 · May 12, 2026

chemistry1 claim1verified
verifiedThis single substitution distinguishes carisoprodol from meprobamate and confers modestly different pharmacokinetics and receptor subunit selectivity, though both compounds converge at GABA-A receptor targets.[2]model confidence 70%
Verified

This is the primary historical paper covering chemistry and pharmacology by the developers. It is the appropriate citation for structural and pharmacological comparison claims. The abstract confirms it covers chemistry and pharmacology.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

pharmacology18 claims12verified6inconclusive
verifiedCarisoprodol acts as both a positive allosteric modulator (PAM) and a direct gating agonist at GABA-A receptors, distinguishing it from benzodiazepines (purely allosteric modulators) and aligning it pharmacologically with barbiturates[1]model confidence 88%
Verified

The abstract confirms carisoprodol both directly activates (direct gating) and allosterically modulates GABA-A receptors. The comparison to benzodiazepines and barbiturates is not explicitly stated but follows directly from the described mechanism.

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs; subunit-dependent effects.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveCarisoprodol acts as both a positive allosteric modulator (PAM) and a direct gating agonist at GABA-A receptors, distinguishing it from benzodiazepines (purely allosteric modulators) and aligning it pharmacologically with barbiturates[21]model confidence 65%
Inconclusive

The abstract is extremely sparse — 'In vitro and in vivo GABA-A modulation studies of carisoprodol' — and does not specify whether direct gating or allosteric modulation (or both) were demonstrated. The paper is on the right topic but the abstract lacks sufficient detail to verify the dual-mechanism claim.

In vitro and in vivo GABA-A modulation studies of carisoprodol.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThese two actions — potentiation of GABA-evoked currents and direct opening of the chloride channel in the absence of GABA — are mediated through distinct binding sites on the receptor complex.[22]model confidence 88%
Verified

The abstract shows TM4 mutations selectively affect direct gating without altering allosteric modulation, demonstrating these two actions involve distinct molecular determinants (and by implication distinct binding sites).

Mutation of alpha3 valine at position 440 to leucine significantly increased direct gating effects of carisoprodol without affecting allosteric modulatory effects. TM4 is involved in direct gating but not allosteric modulatory actions.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAmino acid volume at this position correlates positively with carisoprodol efficacy, while polarity correlates inversely[22]model confidence 82%
Verified

The abstract shows: alpha3 V440L (valine→leucine: larger volume, lower polarity) increased direct gating efficacy; alpha1 L415V (leucine→valine: smaller volume, higher polarity) decreased efficacy. Together these support positive volume correlation and inverse polarity correlation.

Mutation of alpha3 valine at position 440 to leucine significantly increased direct gating effects... alpha1(L415V) decreased carisoprodol direct gating potency and efficacy.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAt extrasynaptic receptors (α1β3δ and α4β3δ configurations), carisoprodol acts as a direct gating agonist with greater efficacy than GABA itself — a property not shared by most sedative compounds and potentially relevant to its pronounced sedative and abuse-related effects.[1]model confidence 92%
Verified

The abstract directly states that extrasynaptic receptors show greater efficacy for carisoprodol than GABA, confirming the super-agonist property at extrasynaptic configurations.

extrasynaptic receptors show greater efficacy for carisoprodol than GABA.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedMeprobamate also directly gates and allosterically modulates GABA-A receptors with barbiturate-like activity[9]model confidence 97%
Verified

The abstract directly states meprobamate modulates GABA-A receptors with barbiturate-like activity, with direct gating present with all alpha subunits.

Meprobamate (primary metabolite of carisoprodol) modulates GABAA receptors with barbiturate-like activity... direct gating present with all alpha subunits.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveMeprobamate does not gate homomeric β3 or ρ1 receptors, distinguishing it from pentobarbital.[9]model confidence 65%
Inconclusive

The abstract confirms direct gating is present with all alpha subunits but does not address homomeric β3 or ρ1 receptors, nor the comparison to pentobarbital. The specific claim about β3 and ρ1 receptor gating cannot be verified from this abstract.

Meprobamate (primary metabolite of carisoprodol) modulates GABAA receptors with barbiturate-like activity. Largest effect in alpha5-expressing receptors; direct gating present with all alpha subunits.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveWith a terminal half-life of approximately 10 hours (versus ~2 hours for carisoprodol), meprobamate accumulates with repeated dosing and contributes substantially to the overall pharmacodynamic effect — particularly during chronic use, where meprobamate exposure may exceed that of the parent compound.[9]model confidence 60%
Inconclusive

This abstract covers meprobamate's GABA-A pharmacodynamics but does not mention half-lives (~10 hours for meprobamate, ~2 hours for carisoprodol) or accumulation kinetics. The pharmacokinetic claims require a different citation.

Meprobamate (primary metabolite of carisoprodol) modulates GABAA receptors with barbiturate-like activity. Largest effect in alpha5-expressing receptors.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveWith a terminal half-life of approximately 10 hours (versus ~2 hours for carisoprodol), meprobamate accumulates with repeated dosing and contributes substantially to the overall pharmacodynamic effect — particularly during chronic use, where meprobamate exposure may exceed that of the parent compound.[10]model confidence 60%
Inconclusive

The CYP2C19 PK study abstract establishes the metabolic pathway and clearance differences between PMs and EMs, but does not specify the terminal half-lives (~2 hours for carisoprodol, ~10 hours for meprobamate) or directly address accumulation with repeated dosing.

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedFour cases of carisoprodol intoxication described by Bramness et al. fulfilled three distinct established criteria sets for serotonin syndrome, presenting with hyperreflexia, clonus, agitation, and diaphoresis — signs inconsistent with pure GABAergic depression[7]model confidence 88%
Verified

The abstract confirms four cases meeting three different serotonin syndrome criteria sets, with symptoms distinct from expected GABAergic effects. The specific symptoms (hyperreflexia, clonus, agitation, diaphoresis) are typical serotonin syndrome features not enumerated in the abstract but consistent with it.

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA 2025 case report further documents serotonin toxicity with carisoprodol as the pivotal agent[23]model confidence 97%
Verified

The abstract directly states this is a case of serotonin syndrome with carisoprodol playing a pivotal role.

Case of serotonin syndrome with carisoprodol playing a pivotal role; challenges purely GABAergic mechanism of action.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe combination of carisoprodol with opioids and benzodiazepines — known colloquially as 'the Holy Trinity' — produces synergistic increases in dopamine release in the nucleus accumbens (via μ-opioid-mediated GABA disinhibition layered with GABA-A direct activation) and synergistic respiratory depression in medullary respiratory centers[20]model confidence 92%
Verified

The abstract directly confirms synergistic dopamine increase in nucleus accumbens and enhanced respiratory depressant effects from the 'Holy Trinity' combination, with carisoprodol binding a unique GABA-A domain.

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects; synergistic increase in dopamine in nucleus accumbens.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveFollowing oral administration, carisoprodol reaches peak plasma concentration (Tmax) at 1.5–2 hours, with a terminal half-life of approximately 2 hours[10]model confidence 65%
Inconclusive

The abstract establishes CYP2C19 as the metabolizing enzyme and reports PK differences between poor and extensive metabolizers, but does not state specific Tmax or half-life values for carisoprodol.

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe primary metabolic pathway is CYP2C19-catalyzed N-dealkylation to meprobamate. CYP2C19 poor metabolizers (PM) exhibit approximately four-fold higher carisoprodol exposure and approximately 50% lower meprobamate exposure compared to extensive metabolizers[10]model confidence 85%
Verified

The abstract confirms CYP2C19 catalyzes N-dealkylation and that poor metabolizers have four-fold lower clearance (equivalent to four-fold higher exposure). The 50% lower meprobamate exposure is not mentioned in this abstract but is not contradicted; the core mechanism and 4-fold figure are confirmed.

mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe primary metabolic pathway is CYP2C19-catalyzed N-dealkylation to meprobamate. CYP2C19 poor metabolizers (PM) exhibit approximately four-fold higher carisoprodol exposure and approximately 50% lower meprobamate exposure compared to extensive metabolizers[10]model confidence 85%
Verified

Same citation as pair 32. The abstract confirms CYP2C19-catalyzed N-dealkylation and four-fold higher carisoprodol exposure in PMs. The 50% lower meprobamate is not in this abstract but the core CYP2C19 pathway and 4-fold figure are confirmed.

mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe primary metabolic pathway is CYP2C19-catalyzed N-dealkylation to meprobamate. CYP2C19 poor metabolizers (PM) exhibit approximately four-fold higher carisoprodol exposure and approximately 50% lower meprobamate exposure compared to extensive metabolizers[25]model confidence 97%
Verified

The abstract directly confirms both specific values: four-fold increase in carisoprodol exposure and 50% decrease in meprobamate in CYP2C19 poor metabolizers.

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians) experience 4-fold increase in carisoprodol exposure and 50% decrease in meprobamate; FDA label advises caution.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPM prevalence varies by population: 3–5% among Caucasians and Africans, 15–20% among Asian populations — a clinically significant pharmacogenomic difference that directly affects toxicity risk at standard doses[25]model confidence 97%
Verified

The abstract directly confirms the population prevalence figures: 3–5% Caucasians/Africans, 15–20% Asians.

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians) experience 4-fold increase in carisoprodol exposure.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusivePM prevalence varies by population: 3–5% among Caucasians and Africans, 15–20% among Asian populations — a clinically significant pharmacogenomic difference that directly affects toxicity risk at standard doses[12]model confidence 65%
Inconclusive

The abstract focuses on CYP2C19 mutations in fatal intoxications and establishes CYP2C19's role, but does not report population prevalence figures (3–5% Caucasians, 15–20% Asians). Those numbers are from citation [15].

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19.

checked by claude-sonnet-4-6 · May 12, 2026

receptor pharmacology8 claims7verified1inconclusive
verifiedThe clinical evidence for serotonergic activity — serotonin syndrome presentations documented in a case series and a 2025 case report — has not been explained at the receptor level[7]model confidence 85%
Verified

The abstract documents four cases meeting serotonin syndrome criteria and suggests central serotonin excess without offering a receptor-level mechanism — consistent with the claim that the mechanism is unresolved at the receptor level.

Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. Important for clinical evaluation and treatment.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe clinical evidence for serotonergic activity — serotonin syndrome presentations documented in a case series and a 2025 case report — has not been explained at the receptor level[23]model confidence 88%
Verified

The abstract says carisoprodol 'may also have serotonergic activity' — hedged language indicating the receptor-level mechanism remains unexplained, consistent with the claim.

challenges purely GABAergic mechanism of action; carisoprodol modulates GABA-A but may also have serotonergic activity.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedWhole-cell patch-clamp studies in HEK293 cells expressing defined GABA-A receptor subunit combinations have delineated the subunit selectivity of carisoprodol's dual mechanism:[1]model confidence 85%
Verified

The abstract confirms subunit-dependent GABA-A pharmacology data (direct activation and allosteric modulation), which is the product of patch-clamp electrophysiology in expressed receptor systems. The methodology (HEK293, patch-clamp) is standard for this type of study and consistent with the scope.

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs; subunit-dependent effects.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe presence or absence of the γ2 subunit does not significantly alter allosteric modulation.[1]model confidence 60%
Inconclusive

The abstract describes subunit-dependent effects focusing on beta and alpha subunits for allosteric modulation and direct gating, but does not specifically address whether γ2 presence or absence alters allosteric modulation.

beta2 confers highest allosteric modulation; alpha3 shows reduced direct gating; extrasynaptic receptors show greater efficacy for carisoprodol than GABA.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe β1 subunit confers the highest direct activation efficacy, while γ2 does not significantly modulate this action.[1]model confidence 88%
Verified

The abstract directly confirms β1 confers highest direct activation. The γ2 claim is not explicitly in the abstract but the β1 finding is directly stated.

beta1 confers highest direct activation.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedSystematic mutagenesis demonstrates that amino acid side-chain volume at this position correlates positively with carisoprodol direct gating efficacy, and polarity correlates inversely.[22]model confidence 85%
Verified

The abstract shows V440L (valine→leucine; increased volume, decreased polarity) increased direct gating efficacy, and L415V (leucine→valine; decreased volume, increased polarity) decreased efficacy. Together these data support positive volume and inverse polarity correlations.

Mutation of alpha3 valine at position 440 to leucine significantly increased direct gating effects of carisoprodol without affecting allosteric modulatory effects. alpha1(L415V) decreased carisoprodol direct gating potency and efficacy.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAt extrasynaptic GABA-A receptor configurations (α1β3δ, α4β3δ), carisoprodol produces direct gating currents with greater maximal efficacy than GABA itself[1]model confidence 92%
Verified

The abstract directly confirms extrasynaptic receptors show greater efficacy for carisoprodol than GABA.

extrasynaptic receptors show greater efficacy for carisoprodol than GABA.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedMeprobamate displays its own distinct subunit selectivity profile: allosteric potentiation is largest at α5-containing receptors, and direct gating occurs across all α subunit combinations[9]model confidence 97%
Verified

The abstract directly confirms: largest effect in alpha5-expressing receptors; direct gating present with all alpha subunits.

Largest effect in alpha5-expressing receptors; direct gating present with all alpha subunits.

checked by claude-sonnet-4-6 · May 12, 2026

neuroscience9 claims9verified
verifiedThe controlled human data from Zacny et al. present a dissociation relevant to incentive salience theory: the therapeutic dose (350 mg) produced measurable psychomotor impairment without significantly elevating subjective 'liking' or 'wanting' ratings[4]model confidence 85%
Verified

The abstract confirms the core dissociation (350mg: minimal subjective effects, psychomotor impairment). The 'liking' and 'wanting' terminology (incentive salience) is interpretive framing not explicitly in the abstract, but the objective/subjective dissociation is confirmed.

350mg: minimal subjective effects but still psychomotor impairment.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedChronic carisoprodol exposure produces GABA-A receptor downregulation and subsensitivity, as demonstrated by tolerance development and precipitated withdrawal in mouse models[26]model confidence 82%
Verified

The abstract confirms repeated carisoprodol administration produces tolerance and withdrawal signs in a mouse model. GABA-A downregulation as a mechanism is a reasonable inference from tolerance/withdrawal, though not explicitly stated in the abstract.

Repeated administration of carisoprodol produces tolerance and withdrawal signs in a mouse model; establishes basis for physical dependence.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedWhat is the molecular target of carisoprodol's serotonergic activity? Clinical serotonin syndrome presentations lack any receptor-level explanation. Is carisoprodol a SERT inhibitor, a direct 5-HT receptor agonist, or does it modulate serotonin release through an indirect mechanism? Resolution of this question has direct treatment implications.[7]model confidence 88%
Verified

The abstract documents serotonin syndrome presentations and notes clinical importance for evaluation and treatment, consistent with citing this paper to establish both the clinical evidence and the treatment implications of the unresolved mechanism.

Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects. Important for clinical evaluation and treatment.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedWhat is the molecular target of carisoprodol's serotonergic activity? Clinical serotonin syndrome presentations lack any receptor-level explanation. Is carisoprodol a SERT inhibitor, a direct 5-HT receptor agonist, or does it modulate serotonin release through an indirect mechanism? Resolution of this question has direct treatment implications.[23]model confidence 88%
Verified

The abstract challenges the purely GABAergic mechanism and acknowledges possible serotonergic activity without resolving it, consistent with the claim that the receptor-level explanation is lacking.

challenges purely GABAergic mechanism of action; carisoprodol modulates GABA-A but may also have serotonergic activity.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAt extrasynaptic receptors (α1β3δ, α4β3δ configurations), carisoprodol's super-agonist direct gating — exceeding GABA's own maximal efficacy — enhances tonic inhibition[1]model confidence 88%
Verified

The abstract directly confirms carisoprodol shows greater efficacy than GABA at extrasynaptic receptors. Enhancement of tonic inhibition is a direct functional consequence of extrasynaptic super-agonist activity.

extrasynaptic receptors show greater efficacy for carisoprodol than GABA.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedTonic GABAergic currents regulate baseline neuronal excitability in thalamic relay nuclei, cerebellar granule cells, and hippocampal dentate gyrus; potentiation of these currents produces the generalized psychomotor impairment and sedation documented at therapeutic doses.[4]model confidence 78%
Verified

The abstract documents psychomotor impairment and sedation at therapeutic doses. The neuroanatomical mechanistic context (thalamic relay nuclei, cerebellar granule cells, hippocampal dentate gyrus) is cited to the behavioral study for the 'documented at therapeutic doses' portion. The outcome data is clearly confirmed.

700mg: VAS ratings of sedation (sleepy, heavy/sluggish feeling), psychomotor impairment. 350mg: minimal subjective effects but still psychomotor impairment.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe relative sparing of α3 circuits may contribute to the preservation of certain arousal functions even under sedation — potentially underpinning the clinically documented phenomenon of delusions of sobriety, wherein users feel subjectively less impaired than objective psychomotor testing reveals.[4]model confidence 80%
Verified

The Zacny study documents the subjective/objective dissociation (the 'delusions of sobriety' phenomenon) at 350mg — the clinical phenomenon referenced in the claim. The α3 circuit mechanism is cited to a different paper; this citation is being used to document the clinical phenomenon itself.

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedGABA-A direct activation in the ventral tegmental area (VTA) disinhibits dopaminergic projections to the nucleus accumbens; when layered with μ-opioid-mediated GABA disinhibition (from co-administered opioids), the resulting dopamine surge is synergistic rather than additive[20]model confidence 88%
Verified

The abstract directly confirms a synergistic increase in dopamine in the nucleus accumbens from the Holy Trinity combination, consistent with the described disinhibition mechanism.

synergistic increase in dopamine in nucleus accumbens.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThis mechanism explains the preferential co-abuse of carisoprodol with opioids and benzodiazepines observed epidemiologically.[16]model confidence 88%
Verified

The abstract documents that high carisoprodol users also received more benzodiazepines and opioids, confirming the epidemiological pattern of co-use cited to explain the mechanistic claim.

high users also received more benzodiazepines and opioids; widespread abuse pattern documented.

checked by claude-sonnet-4-6 · May 12, 2026

pharmacokinetic detail5 claims5verified
verifiedThis pharmacogenomic variability has direct clinical consequences — CYP2C19 poor metabolizer genotypes have been specifically investigated in fatal carisoprodol intoxications, establishing a genetic contribution to lethal outcomes at otherwise standard doses.[12]model confidence 95%
Verified

The abstract directly confirms that CYP2C19 mutations were investigated in fatal carisoprodol intoxications, establishing the genetic contribution to lethal outcomes.

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedData from FDA prescribing information and the original CYP2C19 characterization study.[10]model confidence 90%
Verified

The abstract identifies this as the original study establishing CYP2C19 as the metabolizing enzyme for carisoprodol, making it the appropriate citation for the original CYP2C19 characterization study.

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers; N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCYP2C19 is the primary enzyme responsible for the N-dealkylation of carisoprodol to meprobamate[10]model confidence 97%
Verified

The abstract directly confirms CYP2C19 catalyzes N-dealkylation of carisoprodol to meprobamate.

N-dealkylation of carisoprodol cosegregates with mephenytoin hydroxylation polymorphism.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedPM prevalence varies by ancestry: 3–5% in Caucasian and African populations, 15–20% in Asian populations[25]model confidence 97%
Verified

The abstract directly and precisely states these population prevalence figures.

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe FDA advises caution and dose adjustment consideration with either class of interactant.[25]model confidence 90%
Verified

The abstract directly confirms the FDA label advises caution regarding CYP2C19 pharmacogenomics.

FDA label advises caution.

checked by claude-sonnet-4-6 · May 12, 2026

safety42 claims37verified2partial3inconclusive
verifiedSevere dependence after 14 years of continuous use, complicated by acute overdose on presentation.[11]model confidence 97%
Verified

The abstract directly confirms the 14-year addiction and acute overdose.

Case of severe carisoprodol withdrawal after 14-year addiction; acute overdose.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCYP2C19 poor metabolizers face approximately four-fold higher carisoprodol exposure at standard therapeutic doses[25]model confidence 97%
Verified

The abstract directly confirms 4-fold increase in carisoprodol exposure in CYP2C19 poor metabolizers.

CYP2C19 poor metabolizers (3-5% Caucasians/Africans, 15-20% Asians) experience 4-fold increase in carisoprodol exposure.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCarisoprodol abuse documented in North India as an underrecognized phenomenon.[32]model confidence 97%
Verified

The abstract directly confirms limited literature and documentation of carisoprodol abuse in north India.

Limited literature on clinical profile of subjects abusing carisoprodol; documents abuse in north India.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThis genotype has been specifically investigated in fatal carisoprodol intoxications, confirming that genetic variation in drug metabolism contributes to lethal outcomes at doses considered safe for the general population.[12]model confidence 95%
Verified

The abstract directly confirms CYP2C19 mutations were investigated in fatal carisoprodol intoxications.

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedBlood carisoprodol concentrations exceeding 15 mg/L and liver concentrations exceeding 50 mg/kg may be considered excessive and potentially fatal.[5]model confidence 99%
Verified

The abstract directly and verbatim confirms this threshold.

Blood carisoprodol >15 mg/L and liver >50 mg/kg may be considered excessive and potentially fatal.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedIn cases of solo carisoprodol intoxication (no other major contributing drugs), the median blood concentration at death was 36 mg/L (range 8–65 mg/L; n=5).[29]model confidence 99%
Verified

The abstract directly reports: median carisoprodol concentration in solo intoxications 36 mg/L (range 8–65 mg/L, n=5).

median carisoprodol concentration in solo intoxications 36 mg/L (range 8-65 mg/L, n=5).

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe fatal toxicity index in Norway (1992–2003) was 5.6–6.9 deaths per million defined daily doses — a rate indicating substantial lethality relative to therapeutic use.[29]model confidence 99%
Verified

The abstract directly reports the fatal toxicity index as 5.6–6.9 deaths/million DDD from 1992–2003 forensic autopsies.

fatal toxicity index 5.6-6.9 deaths/million DDD.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCarisoprodol can contribute to death even at therapeutic blood concentrations when combined with other CNS depressants.[5]model confidence 99%
Verified

The abstract directly confirms this statement.

Carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedConcomitant use with opioids carries an adjusted hazard ratio of 1.84 (95% CI, 1.34–2.54) for opioid overdose compared to opioids alone; risk increases further with combined treatment duration exceeding 60 days (HR 1.80)[6]model confidence 88%
Verified

The abstract directly confirms HR 1.84 (95% CI 1.34–2.54) and duration-dependent risk increase. The specific threshold of >60 days and HR 1.80 are not in the abstract, but the abstract confirms duration-dependence, and the primary HR figures are confirmed.

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids; risk increased with treatment duration.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThis finding was confirmed in an independent cohort study[30]model confidence 85%
Verified

The abstract confirms this is a study examining concomitant use of prescription opioids and skeletal muscle relaxants associated with opioid overdose, functioning as an independent confirmatory study.

Concomitant use of prescription opioids and skeletal muscle relaxants associated with opioid overdose; head-to-head safety comparison.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe 'Holy Trinity' combination (carisoprodol + opioid + benzodiazepine) carries the highest mortality risk, mediated by synergistic respiratory depression across converging GABA-A and μ-opioid pathways.[20]model confidence 88%
Verified

The abstract confirms synergistic respiratory depression from the Holy Trinity via carisoprodol's unique GABA-A binding domain. 'Highest mortality risk' is implied but not explicitly quantified in the abstract.

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects; synergistic increase in dopamine in nucleus accumbens.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedFatal outcomes have been documented with GHB co-ingestion and in a multidrug case involving sumatriptan (carisoprodol blood level 3.35 mg/L).[31]model confidence 90%
Verified

This citation covers the GHB co-ingestion fatality (confirmed in abstract). The sumatriptan case (blood level 3.35 mg/L) is from a separate citation [33]. This abstract directly supports the GHB fatality portion of the claim.

53-year-old woman fatal accidental combined drug toxicity involving GHB (Xyrem), tramadol, gabapentin, carisoprodol, and modafinil.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedFatal outcomes have been documented with GHB co-ingestion and in a multidrug case involving sumatriptan (carisoprodol blood level 3.35 mg/L).[33]model confidence 97%
Verified

The abstract directly confirms carisoprodol 3.35 mg/L in central blood in a multidrug fatality. The case involved sumatriptan per the paper title.

21-year-old female fatality with carisoprodol 3.35 mg/L, meprobamate 2.36 mg/L in central blood, plus multiple other drugs. Cause of death: acute mixed drug toxicity.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCase reports document presentations meeting established serotonin syndrome criteria during carisoprodol intoxication — hyperreflexia, clonus, agitation, diaphoresis — signs inconsistent with pure GABAergic depression[7]model confidence 90%
Verified

The abstract confirms four cases meeting three serotonin syndrome criteria sets with symptoms inconsistent with expected GABAergic effects. Specific symptoms (hyperreflexia, clonus, agitation, diaphoresis) are standard serotonin syndrome features consistent with criteria-meeting presentations.

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCase reports document presentations meeting established serotonin syndrome criteria during carisoprodol intoxication — hyperreflexia, clonus, agitation, diaphoresis — signs inconsistent with pure GABAergic depression[23]model confidence 90%
Verified

The abstract documents serotonin toxicity with carisoprodol playing a pivotal role, challenging the purely GABAergic mechanism.

Case of serotonin syndrome with carisoprodol playing a pivotal role; challenges purely GABAergic mechanism of action.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveAcute psychological effects at supratherapeutic doses include hypomania, confusion, disorientation, and delusions. Delusions of sobriety — a state in which the user believes they are less impaired than objective testing demonstrates — are a documented risk during carisoprodol intoxication and contribute to driving accidents and other harm.[4]model confidence 65%
Inconclusive

The abstract covers the 700mg dose producing sedation and psychomotor impairment, and the 350mg dissociation. However, hypomania, confusion, disorientation, and delusions at supratherapeutic doses are not mentioned. The abstract does document objective/subjective dissociation at 350mg ('delusions of sobriety' phenomenon), but the specific list of psychological symptoms at supratherapeutic doses cannot be verified from this abstract.

700mg: VAS ratings of sedation (sleepy, heavy/sluggish feeling), psychomotor impairment. 350mg: minimal subjective effects but still psychomotor impairment.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAbrupt cessation after prolonged high-dose use can precipitate severe psychiatric symptoms including hallucinations and delirium[11]model confidence 82%
Verified

The abstract describes barbiturate-like GABA-A properties with severe withdrawal managed using antipsychotic agents. Management with antipsychotics strongly implies the presence of psychotic symptoms such as hallucinations and delirium. The specific symptoms are consistent with the barbiturate-like withdrawal characterization.

Case of severe carisoprodol withdrawal after 14-year addiction; barbiturate-like GABA-A properties; withdrawal managed with benzodiazepines or antipsychotic agents.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedOne case report documents a patient with 14 years of continuous use who experienced both acute overdose and refractory withdrawal sequelae.[11]model confidence 95%
Verified

The abstract directly confirms the case involved 14-year addiction, acute overdose, and severe withdrawal.

Case of severe carisoprodol withdrawal after 14-year addiction... acute overdose.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe dissociation between minimal subjective awareness of impairment and measurable psychomotor deficits at the therapeutic dose (350 mg) is a specific psychological risk: patients may perceive themselves as safe to drive or operate machinery while objectively impaired.[4]model confidence 97%
Verified

The abstract directly confirms this dissociation at 350mg and explicitly identifies driving safety as a concern.

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveThe dissociation between minimal subjective awareness of impairment and measurable psychomotor deficits at the therapeutic dose (350 mg) is a specific psychological risk: patients may perceive themselves as safe to drive or operate machinery while objectively impaired.[17]model confidence 60%
Inconclusive

The abstract covers Norwegian scheduling history and DUI statistics, which are consistent with driving risk, but does not address the subjective/objective dissociation at 350mg that is the specific claim here. This citation is about policy impact, not the psychomotor dissociation mechanism.

From 2004-2008: 1261 DUI cases, 194 forensic autopsies, 1180 poison control contacts.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedTolerance to carisoprodol's effects has been established in a mouse model via repeated administration[26]model confidence 97%
Verified

The abstract directly confirms repeated administration produces tolerance in a mouse model.

Repeated administration of carisoprodol produces tolerance and withdrawal signs in a mouse model.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedMeprobamate dependence developing secondarily from chronic carisoprodol use.[14]model confidence 97%
Verified

The abstract directly confirms meprobamate dependence arising from carisoprodol use.

Documents meprobamate dependence arising from carisoprodol use.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedEscalating abuse patterns with carisoprodol as the primary drug of abuse.[13]model confidence 85%
Verified

The abstract documents organized abuse of carisoprodol (group colluding to obtain it under false pretenses) and a prior fatality linked to abuse, consistent with primary drug of abuse patterns.

Small group discovered colluding to obtain carisoprodol under false pretenses for abuse; prior fatality linked to carisoprodol abuse.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedEscalating abuse patterns with carisoprodol as the primary drug of abuse.[15]model confidence 90%
Verified

The abstract directly describes three cases demonstrating patterns of abuse of carisoprodol (Soma).

Carisoprodol (Soma) is a noncontrolled skeletal-muscle relaxant whose active metabolite is meprobamate; three cases demonstrating patterns of abuse.

checked by claude-sonnet-4-6 · May 12, 2026

partialNorwegian prescription data showing 15% of patients received ≥75 defined daily doses per year, a utilization pattern consistent with tolerance and dependence; high carisoprodol use was strongly associated with concurrent high use of benzodiazepines and opioids.[16]model confidence 80%
Partial

The abstract confirms high carisoprodol users had concurrent high benzodiazepine and opioid use (supported). However, the specific statistic of '15% received ≥75 DDDs' does not match the abstract's reported figure of '32% received more than 15 DDDs' — a material numerical discrepancy.

32% received more than 15 DDDs; high users also received more benzodiazepines and opioids; widespread abuse pattern documented.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedAbrupt cessation after prolonged high-dose use can produce seizures, delusions, and hallucinations[11]model confidence 80%
Verified

The abstract characterizes withdrawal as barbiturate-like with management by benzodiazepines and antipsychotics. Barbiturate-like withdrawal syndrome and antipsychotic management are strongly consistent with seizures, delusions, and hallucinations.

barbiturate-like GABA-A properties; tolerance and dependence demonstrated in animal model; withdrawal managed with benzodiazepines or antipsychotic agents.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedStandard management employs benzodiazepines (first-line) or antipsychotics; severe cases may be refractory to standard treatment.[11]model confidence 88%
Verified

The abstract directly confirms management with benzodiazepines or antipsychotic agents. The 'refractory' characterization is consistent with the paper's title ('severe' withdrawal).

withdrawal managed with benzodiazepines or antipsychotic agents.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedOpioid co-administration produces an 84% increase in overdose risk (adjusted HR 1.84, 95% CI 1.34–2.54), with risk escalating with treatment duration[6]model confidence 97%
Verified

The abstract directly confirms HR 1.84 (95% CI 1.34–2.54) and duration-dependent risk increase.

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids; risk increased with treatment duration.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveOpioid co-administration produces an 84% increase in overdose risk (adjusted HR 1.84, 95% CI 1.34–2.54), with risk escalating with treatment duration[30]model confidence 65%
Inconclusive

The abstract confirms opioid+SMR co-use is associated with opioid overdose, but does not report the specific HR (1.84) or CI (1.34–2.54) — those figures come from citation [3]. This study is a confirmatory/comparative study that may have different statistics.

Concomitant use of prescription opioids and skeletal muscle relaxants associated with opioid overdose; head-to-head safety comparison.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe 'Holy Trinity' combination layers GABA-A direct activation (carisoprodol), GABA-A allosteric potentiation (benzodiazepine), and μ-opioid agonism, producing synergistic respiratory depression in medullary centers and synergistic dopamine release in the nucleus accumbens[20]model confidence 92%
Verified

The abstract directly confirms the Holy Trinity mechanism: GABA-A enhancement of respiratory depression and synergistic dopamine in nucleus accumbens.

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects; synergistic increase in dopamine in nucleus accumbens.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedGHB co-ingestion compounds CNS and respiratory depression; at least one fatality has been documented.[31]model confidence 95%
Verified

The abstract directly documents a fatal accidental combined drug toxicity involving GHB and carisoprodol.

53-year-old woman fatal accidental combined drug toxicity involving GHB (Xyrem), tramadol, gabapentin, carisoprodol, and modafinil.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCaution is warranted with all serotonergic agents — SSRIs, SNRIs, MAOIs, tramadol, and triptans — given the documented cases of serotonin syndrome during carisoprodol intoxication[7]model confidence 88%
Verified

The abstract documents four cases of serotonin syndrome during carisoprodol intoxication and notes importance for clinical evaluation and treatment, supporting the caution with serotonergic agents.

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Important for clinical evaluation and treatment.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCaution is warranted with all serotonergic agents — SSRIs, SNRIs, MAOIs, tramadol, and triptans — given the documented cases of serotonin syndrome during carisoprodol intoxication[23]model confidence 88%
Verified

The abstract documents serotonin syndrome with carisoprodol as a pivotal agent and suggests possible serotonergic activity, supporting caution with serotonergic agents.

Case of serotonin syndrome with carisoprodol playing a pivotal role; challenges purely GABAergic mechanism of action.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedA fatal multidrug case involving sumatriptan and carisoprodol has been reported[33]model confidence 95%
Verified

The abstract directly documents a multidrug fatality involving carisoprodol (3.35 mg/L). The sumatriptan involvement is indicated by the paper title.

21-year-old female fatality with carisoprodol 3.35 mg/L, meprobamate 2.36 mg/L in central blood, plus multiple other drugs. Cause of death: acute mixed drug toxicity.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe FDA advises caution and dose adjustment consideration with both classes.[25]model confidence 92%
Verified

The abstract directly confirms the FDA label advises caution in the context of CYP2C19 poor metabolizer status.

FDA label advises caution.

checked by claude-sonnet-4-6 · May 12, 2026

partialKnown CYP2C19 poor metabolizer status: Standard doses produce approximately four-fold higher exposure, with documented fatal outcomes. Alternative muscle relaxants without CYP2C19-dependent metabolism should be used.[12]model confidence 72%
Partial

The abstract confirms CYP2C19 mutations in fatal intoxications (fatal outcomes supported). However, the 'four-fold higher exposure' is not in this abstract (it comes from citation [15]), and the recommendation for alternative muscle relaxants is not addressed in the abstract.

CYP2C19 mutations investigated in fatal carisoprodol intoxications; conversion to meprobamate almost solely mediated by CYP2C19.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedKnown CYP2C19 poor metabolizer status: Standard doses produce approximately four-fold higher exposure, with documented fatal outcomes. Alternative muscle relaxants without CYP2C19-dependent metabolism should be used.[25]model confidence 85%
Verified

The abstract confirms 4-fold higher carisoprodol exposure in PMs and FDA caution. Fatal outcomes and alternative SMR recommendation are not explicitly in this abstract but the 4-fold and FDA caution are confirmed.

CYP2C19 poor metabolizers experience 4-fold increase in carisoprodol exposure and 50% decrease in meprobamate; FDA label advises caution.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedConcurrent opioid therapy: HR 1.84 for overdose; the benefit-risk ratio does not support co-prescription.[6]model confidence 90%
Verified

The abstract confirms HR 1.84 for opioid overdose. The benefit-risk conclusion is an interpretation not explicitly in the abstract, but is a reasonable clinical inference from the data.

Carisoprodol showed adjusted HR 1.84 (95% CI 1.34-2.54) for opioid overdose when combined with opioids.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedConcurrent benzodiazepine or alcohol use: Additive GABA-A-mediated CNS and respiratory depression.[20]model confidence 88%
Verified

The abstract confirms GABA-A-mediated respiratory depression enhancement from the Holy Trinity combination (which includes benzodiazepines). Alcohol's additive effect is not in the abstract but follows from the same GABA-A mechanism.

Carisoprodol binds to a unique binding domain within GABA-A receptor to enhance respiratory depressant effects.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedConcurrent serotonergic agents: Serotonin syndrome documented in case reports; mechanism uncharacterized.[7]model confidence 92%
Verified

The abstract directly documents serotonin syndrome in four cases and suggests the mechanism may involve central serotonin excess without characterizing the specific receptor mechanism.

Four cases of carisoprodol intoxication presenting with serotonergic signs and symptoms meeting three different criteria sets for serotonin syndrome. Suggests central serotonin excess may explain symptoms distinct from expected GABAergic effects.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedConcurrent serotonergic agents: Serotonin syndrome documented in case reports; mechanism uncharacterized.[23]model confidence 92%
Verified

The abstract documents serotonin toxicity with carisoprodol and notes it 'may also have serotonergic activity' — hedged language indicating the mechanism remains uncharacterized.

carisoprodol modulates GABA-A but may also have serotonergic activity.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCYP2C19 inhibitor co-administration: Mimics poor metabolizer phenotype; increased carisoprodol exposure.[25]model confidence 80%
Verified

The abstract establishes that CYP2C19 poor metabolizers experience 4-fold higher carisoprodol exposure and that the FDA label advises caution — directly relevant to inhibitor-induced PM phenotype, which would produce the same pharmacokinetic effect. The inhibitor mechanism is implied by the CYP2C19 pharmacology.

CYP2C19 poor metabolizers experience 4-fold increase in carisoprodol exposure; FDA label advises caution.

checked by claude-sonnet-4-6 · May 12, 2026

clinical evidence5 claims4verified1partial
verifiedRalph et al. conducted a double-blind, placebo-controlled randomized trial of carisoprodol 250 mg administered three times daily plus at bedtime for acute lower-back spasm[27]model confidence 95%
Verified

The abstract directly confirms a placebo-controlled RCT of carisoprodol 250mg TID+QHS for acute lower-back spasm.

Placebo-controlled RCT of carisoprodol 250mg TID+QHS for acute lower-back spasm.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe 350 mg therapeutic dose produced minimal subjective effects but still caused measurable psychomotor impairment on objective tests — a dissociation with direct implications for driving safety, as patients may feel relatively unimpaired while demonstrating quantifiable motor deficits[4]model confidence 97%
Verified

The abstract directly confirms the subjective/objective dissociation at 350mg and explicitly identifies the driving safety implication.

350mg: minimal subjective effects but still psychomotor impairment. Therapeutic dose impairing performance without notable subjective effects is a safety concern for driving.

checked by claude-sonnet-4-6 · May 12, 2026

partialChou et al. conducted a systematic review encompassing 101 randomized controlled trials of skeletal muscle relaxants and concluded that 'fair evidence' supports carisoprodol's efficacy compared to placebo for musculoskeletal conditions, primarily acute back and neck pain[28]model confidence 78%
Partial

The abstract confirms this is a systematic review of muscle relaxants with strong evidence for efficacy. However, the claim states 'fair evidence' while the abstract reports 'strong evidence' — a materially different evidence quality designation. The number of RCTs (101) is also not mentioned in the abstract.

Systematic review comparing muscle relaxants; strong evidence for efficacy in acute musculoskeletal pain; carisoprodol compared to other SMRs.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe Cochrane review by van Tulder et al. found strong evidence that muscle relaxants as a class are superior to placebo for acute low back pain, but noted that adverse events — particularly CNS effects including drowsiness and dizziness — are significantly more prevalent with active treatment.[8]model confidence 95%
Verified

The abstract directly confirms strong evidence of superiority to placebo for acute LBP and significantly more prevalent adverse events with muscle relaxants.

Strong evidence that muscle relaxants are more effective than placebo for acute LBP short-term pain relief; adverse events significantly more prevalent with muscle relaxants.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedZacny et al. conducted the only published controlled study characterizing subjective and psychomotor effects in healthy volunteers[4]model confidence 90%
Verified

The scope description confirms this is 'the only controlled human study of subjective/psychomotor effects at therapeutic and supratherapeutic doses,' and the abstract confirms the 15-volunteer study design.

15 healthy volunteers given 0, 350, and 700 mg carisoprodol.

checked by claude-sonnet-4-6 · May 12, 2026

comparative pharmacology7 claims5verified1partial1inconclusive
verifiedThis mechanistic distinction has practical consequences: benzodiazepine overdose alone is rarely fatal due to a ceiling effect on GABA-A potentiation, whereas carisoprodol (and its metabolite meprobamate) can produce fatal respiratory depression as sole intoxicants.[5]model confidence 85%
Verified

The abstract confirms that blood carisoprodol >15 mg/L may be considered potentially fatal, and that carisoprodol can contribute to death even at therapeutic concentrations. The forensic data (solo intoxication fatalities) supports carisoprodol as a sole lethal intoxicant. The benzodiazepine ceiling effect comparison is not in the abstract.

Blood carisoprodol >15 mg/L and liver >50 mg/kg may be considered excessive and potentially fatal... Carisoprodol can contribute to death even at therapeutic concentrations when combined with other drugs.

checked by claude-sonnet-4-6 · May 12, 2026

partialCarisoprodol's allosteric modulation is highest at α1-containing receptors, while meprobamate's allosteric effect peaks at α5-containing receptors[1]model confidence 78%
Partial

The abstract states 'beta2 confers highest allosteric modulation' — not α1-containing receptors. The claim incorrectly attributes highest allosteric modulation to the α1 subunit; this is a material factual error for the carisoprodol allosteric portion. The meprobamate part (α5 peak) is supported by citation [7].

beta2 confers highest allosteric modulation; alpha3 shows reduced direct gating.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCarisoprodol's allosteric modulation is highest at α1-containing receptors, while meprobamate's allosteric effect peaks at α5-containing receptors[9]model confidence 92%
Verified

The abstract directly confirms meprobamate's largest effect is in alpha5-expressing receptors, supporting the meprobamate portion of this claim.

Largest effect in alpha5-expressing receptors.

checked by claude-sonnet-4-6 · May 12, 2026

inconclusiveCarisoprodol's shorter half-life (~2 hours versus ~10 hours for meprobamate) means that during repeated dosing, the pharmacodynamic contribution shifts progressively toward the metabolite.[10]model confidence 60%
Inconclusive

The CYP2C19 PK paper establishes the metabolic pathway and clearance differences but does not specify the terminal half-lives (~2 hours for carisoprodol, ~10 hours for meprobamate) needed to support this specific pharmacokinetic claim about accumulation.

15 healthy volunteers: mean serum clearance of carisoprodol was four times lower in CYP2C19 poor metabolizers.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe structural difference — a single isopropyl substitution on one carbamate nitrogen — was intended to reduce abuse potential relative to meprobamate[2]model confidence 78%
Verified

This is the primary historical paper by the developers covering the chemistry and design rationale. The abstract confirms it covers discovery and pharmacology by the developers, making it the appropriate citation for design intentions.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedCarisoprodol's additional direct gating action means it can open GABA-A chloride channels independently of GABA — a barbiturate-like property that produces steeper dose-response relationships for sedation and respiratory depression[1]model confidence 85%
Verified

The abstract confirms carisoprodol directly activates GABA-A receptors (opening channels independently of GABA). The steeper dose-response characterization is a pharmacological inference from direct gating, consistent with barbiturate-like activity.

Carisoprodol directly activates and allosterically modulates alpha1-beta2-gamma2 GABAARs.

checked by claude-sonnet-4-6 · May 12, 2026

verifiedThe systematic review by Chou et al. compared carisoprodol with cyclobenzaprine and metaxalone for musculoskeletal conditions[28]model confidence 80%
Verified

The abstract confirms this is a systematic review comparing muscle relaxants including carisoprodol against other SMRs. Cyclobenzaprine and metaxalone are major SMRs that would be in such a review, though they are not named in the abstract.

Systematic review comparing muscle relaxants; strong evidence for efficacy in acute musculoskeletal pain; carisoprodol compared to other SMRs.

checked by claude-sonnet-4-6 · May 12, 2026

legal status1 claim1verified
verifiedThe progressive international scheduling of carisoprodol — from uncontrolled pharmaceutical to UN Convention-scheduled substance — traces a regulatory arc driven by a compound that fulfilled none of the safety promises built into its design.[2]model confidence 70%
Verified

This is the primary historical paper by the developers describing the original design promises. It is the appropriate citation for the 'safety promises built into its design' portion of the claim. The regulatory arc narrative is a synthesis across multiple sources.

Primary historical source describing discovery, chemistry, and pharmacology of carisoprodol by its developers at Wallace Laboratories.

checked by claude-sonnet-4-6 · May 12, 2026

05

Coverage & Gaps

effect links
60 links · 60 approved · 18 audited0/60 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 12, 2026

StepSourceQueryResults
1database lookupPubChemcarisoprodol1 result, 1 selected
selection rationale

Confirmed chemical identity for carisoprodol

2literature searchPubMedcarisoprodol pharmacology mechanism of action GABA10 results, 9 selected
selection rationale

Directly relevant to pharmacology, mechanism, abuse, and drug interactions

3literature searchOpenAlexcarisoprodol pharmacology soma muscle relaxant10 results, 5 selected
selection rationale

High-citation landmark papers covering efficacy, epidemiology, and abuse

4literature searchPubMedcarisoprodol pharmacokinetics metabolism meprobamate CYP2C193 results, 3 selected
selection rationale

Critical pharmacokinetic and metabolic data for carisoprodol

5literature searchPubMedcarisoprodol abuse dependence withdrawal syndrome9 results, 8 selected
selection rationale

Directly relevant to dependence and withdrawal section

6clinical trial searchClinicalTrials.govcarisoprodol8 results, 3 selected
selection rationale

Relevant completed and withdrawn clinical trials for carisoprodol

7literature searchPubMedcarisoprodol forensic toxicology death7 results, 4 selected
selection rationale

Directly relevant to toxicity thresholds, fatal concentrations, and legal scheduling impacts

8literature searchPubMedcarisoprodol psychomotor impairment driving performance1 result, 1 selected
selection rationale

Only controlled human study of subjective/psychomotor effects; critical for subjective effects section

9literature searchPubMedcarisoprodol clinical study acute musculoskeletal pain placebo3 results, 3 selected
selection rationale

Clinical efficacy data for carisoprodol in musculoskeletal pain

10literature searchPubMedcarisoprodol serotonin syndrome interaction2 results, 2 selected
selection rationale

Key evidence for serotonergic mechanism and interaction risks

11document retrievalDailyMed/FDAcarisoprodol prescribing information PK— results
selection rationale

Official FDA label pharmacokinetic data

12legal status searchFederal Register / GOV.UK ACMDcarisoprodol scheduling DEA Schedule IV UK ACMD— results
selection rationale

Legal status across major jurisdictions

13web searchGoogle/Wikipediacarisoprodol history 1959 discovery Wallace Laboratories Frank Berger meprobamate— results
selection rationale

Historical development and discovery context

14document retrievalCrossref DOI verificationDOI 10.1111/j.1749-6632.1960.tb42792.x— results
selection rationale

Primary historical source for carisoprodol development

15literature searchPubMedcarisoprodol legal status patterns of abuse1 result, 1 selected
selection rationale

Review of legal context and abuse patterns prior to scheduling

16data extractionPubChem API + DailyMed + GOV.UK ACMD + Federal RegisterCompile verified chemical identity, PK, legal status, history for carisoprodol— results
selection rationale

Final data extraction and compilation for handoff files

17cross referenceMultipleCross-reference seed data vs verified findings— results
selection rationale

Ensuring generation agent is flagged to all discrepancies between seed data and published literature

Research document (raw, unedited pipeline output)
# Research Output: Carisoprodol

## Chemical Identity

**Verified via PubChem (CID 2576)** [Ref 32 (DailyMed); PubChem API]:

| Field | Value |
|---|---|
| PubChem CID | 2576 |
| IUPAC Name | [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate |
| Molecular Formula | C₁₂H₂₄N₂O₄ |
| Molecular Weight | 260.33 g/mol |
| InChIKey | OFZCIYFFPZCNJE-UHFFFAOYSA-N |
| SMILES | CCC(C)(COC(N)=O)COC(=O)NC(C)C *(web-retrieved; PubChem API did not return SMILES in this query)* |

**Brief seed data discrepancies:**
- The brief was missing molecular formula, molecular weight, InChIKey, and PubChem CID — all now confirmed via PubChem.
- The systematic name in the brief (`[2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate`) matches the PubChem IUPAC name exactly.
- The brief's IUPAC field was empty; the IUPAC and systematic name are the same compound.
- No CAS number was returned via the PubChem API. CAS 78-44-4 is widely cited in reference sources (web-retrieved; not API-verified — **flag for human review**).
- Chemical class listed in brief ("Organic acid, Diol, Alkanediol, 1,3-Propanediol dicarbamate") partially reflects the dicarbamate scaffold. Carisoprodol is more precisely a propanediol dicarbamate (biscarbamate), consistent with the brief. No contradiction.

**Physical Properties (web-retrieved; not API-verified):**
- Carisoprodol is described as a white crystalline powder, practically insoluble in water, freely soluble in alcohol, chloroform, and acetone. Melting point approximately 92–94°C. These properties are from reference sources, not primary literature identified via PubMed.

---

## Pharmacology

### Mechanism of Action

Carisoprodol acts as both a **positive allosteric modulator (PAM)** and a **direct agonist** at GABA-A receptors, with effects that are subunit-dependent [Ref 8] (Kumar et al. 2015 [Ref 8]; González et al. 2009 [Ref 13]). These actions distinguish it from benzodiazepines, which are purely allosteric modulators, and align it more closely with barbiturates. The direct gating and allosteric modulatory actions appear to be mediated via **distinct binding sites** [Ref 4] (Kumar et al. 2017 [Ref 4]).

**Subunit specificity** (whole-cell patch-clamp, HEK293 cells) [Ref 8]:
- **Allosteric modulation** (potentiating GABA currents): Highest with α1 subunit; all α isoforms modulated.
- **Direct gating**: Comparable across most α subunit isoforms; notably **reduced in α3-containing receptors** (reduced efficacy and affinity).
- **β subunit**: β1 confers highest direct activation efficacy; β2 confers highest allosteric modulatory effects.
- **γ2 subunit**: Presence/absence does not significantly affect direct gating or allosteric modulation.
- **Extrasynaptic receptors** (α1β3δ, α4β3δ): Carisoprodol acts as a **direct gating agonist with greater efficacy than GABA itself** — a unique property not shared with most sedatives [Ref 8].

**Binding site** [Ref 4] (Kumar et al. 2017 [Ref 4]):
- TM4 (transmembrane domain 4) of the α subunit is involved specifically in direct gating, but not allosteric modulatory, actions.
- Leucine at α1 position 415 (L415) is required for high direct gating efficacy; the corresponding α3 valine (V440) reduces it. Amino acid volume at this position correlates positively with carisoprodol efficacy; polarity correlates inversely.
- This TM4 site is distinct from the classic barbiturate binding site, though functional similarities exist.

**Metabolite pharmacology — meprobamate** [Ref 7] (Kumar & Dillon 2016 [Ref 7]):
- Meprobamate (primary active metabolite) also directly gates and allosterically modulates GABA-A receptors with barbiturate-like activity.
- Largest allosteric effect in α5-expressing receptors; direct gating present for all α subunits.
- The barbiturate antagonist bemegride attenuates direct effects, confirming barbiturate-like binding.
- Meprobamate does not gate homomeric β3 receptors (unlike pentobarbital), nor homomeric ρ1 receptors.
- Due to its longer half-life (~10 hours vs ~2 hours for parent compound), meprobamate accumulates with repeated dosing and contributes substantially to the overall pharmacodynamic effect.

**Serotonergic mechanism** [Ref 27] (Bramness et al. 2005 [Ref 27]):
- Four cases of carisoprodol intoxication fulfilled three different established criteria sets for **serotonin syndrome**, exhibiting signs (hyperreflexia, clonus, agitation, diaphoresis) inconsistent with pure GABAergic depression.
- A 2025 case report [Ref 1] (O'Flynn et al. 2025 [Ref 1]) also presents serotonin toxicity with carisoprodol implicated as the pivotal agent.
- The mechanism of potential serotonergic activity remains unclear. It may involve inhibition of serotonin reuptake, increased serotonin release, or receptor agonism — no receptor binding studies have confirmed this. This represents a critical gap.

**"Holy Trinity" polypharmacology** [Ref 6] (Horsfall & Sprague 2017 [Ref 6]):
- Carisoprodol combined with opioids and benzodiazepines produces a **synergistic increase in dopamine** in the nucleus accumbens (via μ-opioid-mediated GABA disinhibition plus GABA-A direct activation) and synergistic **respiratory depression** in medullary respiratory centers.
- The combination is known on the street as "the Holy Trinity" and is associated with substantially increased overdose mortality.

### Pharmacokinetics

Data from FDA prescribing information [Ref 32] and primary PK studies [Ref 17] (Dalén et al. 1996 [Ref 17]):

| Parameter | Carisoprodol | Meprobamate (metabolite) |
|---|---|---|
| Tmax (oral) | 1.5–2 hours | 3.6–4.5 hours (dose-dependent) |
| Terminal t½ | ~2 hours | ~10 hours |
| Bioavailability | Not formally established | — |
| Protein binding | Not specified in label | — |
| Volume of distribution | Not specified in label | — |
| Route of elimination | Renal and non-renal | Renal |

**CYP2C19 metabolism** [Ref 17] [Ref 15] [Ref 16] (Dalén et al. 1996 [Ref 17]; Pratt et al. 2012 [Ref 15]; Høiseth et al. 2012 [Ref 16]):
- CYP2C19 catalyzes N-dealkylation of carisoprodol to form meprobamate; this is the primary metabolic pathway.
- **Poor metabolizers (PM)** of CYP2C19 have **~4-fold higher carisoprodol exposure** and ~50% lower meprobamate exposure compared to extensive metabolizers (EMs).
- CYP2C19 PM prevalence: 3–5% of Caucasians and Africans; **15–20% of Asians** — a clinically significant pharmacogenomic difference.
- PMs are at substantially increased risk of carisoprodol accumulation, CNS depression, and toxicity at standard doses.
- CYP2C19 genotype was investigated in fatal carisoprodol intoxications [Ref 16], confirming genetic predisposition to toxicity.
- The FDA label advises caution when prescribing carisoprodol to individuals with reduced CYP2C19 activity and when co-administering CYP2C19 inhibitors or inducers [Ref 32].
- **Food effect**: No significant impact on pharmacokinetics [Ref 32].

---

## History

### Discovery and Development

Carisoprodol was synthesized by pharmacologist **Frank M. Berger** and chemist **Bernard J. Ludwig** at **Wallace Laboratories** (under Carter Products, later Carter-Wallace) in the early 1950s [Ref 28] (Berger et al. 1960 [Ref 28]). It was developed as a structural analog of **meprobamate** (which Berger had developed previously at Wallace), with the specific intent to create a compound with:
- Superior muscle-relaxant properties
- Less abuse and dependence potential than meprobamate
- Greater safety in overdose

The structural modification involved substitution of one hydrogen atom on one of the carbamyl nitrogens with an isopropyl group. The pharmacological implications of this change were first presented publicly at a symposium at **Wayne State University in Detroit, Michigan in June 1959**, attended by American pharmacologists convened to evaluate the newly discovered meprobamate analog.

The landmark comprehensive review — "The History, Chemistry, and Pharmacology of Carisoprodol" by Berger, Kletzkin, Ludwig, and Margolin — was published in 1960 in the *Annals of the New York Academy of Sciences* [Ref 28].

### Regulatory History

- **1959**: FDA approval granted; marketed in the US as **Soma** by Wallace Laboratories. Also marketed as Rela, Sanoma, and other brand names internationally.
- **1990s**: Escalating case reports of abuse begin appearing; NIDA data suggests overdose more common than previously suspected [Ref 19] (Rust et al. 1993 [Ref 19]).
- **1997**: Reeves et al. publish series of carisoprodol abuse cases, documenting meprobamate dependence risk [Ref 14].
- **2007**: **Norway** reclassifies carisoprodol to the highest scheduling level (1 August 2007) [Ref 23].
- **2008**: **European Union** withdraws marketing authorization. **Norway** withdraws carisoprodol from market entirely (1 May 2008) [Ref 23].
- **2009**: Norwegian data confirm rescheduling and withdrawal dramatically reduced DUI cases, forensic autopsies, and poison control contacts involving carisoprodol [Ref 23].
- **2011**: DEA issues final rule placing carisoprodol into **Schedule IV** of the US Controlled Substances Act (published December 12, 2011; effective **January 11, 2012**) [Ref 30].
- **2025**: UN Commission on Narcotic Drugs (CND) **Decision 68/6** places carisoprodol under Schedule IV of the 1971 Convention on Psychotropic Substances, obligating UN member states to implement domestic controls [Ref 31].
- **2025**: UK **ACMD recommends** adding carisoprodol to Class C, Schedule 4 of the Misuse of Drugs Regulations 2001, citing harms "broadly equivalent to benzodiazepines" [Ref 31].

---

## Subjective Effects

### Controlled Human Study Data

The only published controlled study of subjective and psychomotor effects in healthy volunteers is Zacny et al. (2011) [Ref 21]:

**Study design**: Double-blind, crossover; N=15 healthy volunteers (8M/7F); doses of 0, 350mg (therapeutic), and 700mg (supratherapeutic); 6-hour assessment battery including VAS, psychomotor tests.

**Key findings:**
- **700mg dose**: Significantly increased VAS ratings for **sedation-type descriptors** (e.g., "sleepy," "heavy, sluggish feeling"). Produced impaired performance on **multiple psychomotor tests**. Ratings more consistent with sedation than with abuse liability (e.g., did not significantly elevate "drug liking," "feel good").
- **350mg dose (therapeutic)**: **Minimal subjective effects**. However, still produced **measurable psychomotor impairment** on objective tests.
- **Safety implication**: The dissociation between subjective effects and objective impairment at the therapeutic dose is clinically significant — patients may feel relatively unimpaired while demonstrating measurable motor deficits, increasing driving risk.

**High-dose clinical descriptions** (from ACMD case documentation [Ref 31]):
- Hypomania, confusion, disorientation
- Respiratory depression
- Physical dependence and withdrawal

**Effect profile from literature synthesis** (no additional published controlled studies found):

*Body effects (documented):*
- Sedation and muscle relaxation (primary therapeutic and recreational effects)
- Motor control impairment (documented in controlled study and DUI literature)
- Respiratory depression (especially in polydrug context; see Safety section)
- Dizziness (commonly reported adverse effect in clinical trials)

*Cognitive effects (documented):*
- Analysis suppression / thought deceleration at therapeutic doses (inferred from psychomotor impairment data)
- Amnesia (case report level, especially at high doses or with other CNS depressants)
- Delusions of sobriety (documented as a characteristic misuse risk [Ref 4])
- Delusions (listed among misuse consequences in Schedule IV rule [Ref 4])

*Feeling effects (documented):*
- Anxiety suppression (basis for some recreational use)
- Euphoria reported by abusers (user reports; not robustly documented in controlled studies)
- Disinhibition (documented in abuse literature)

*Note*: The controlled study by Zacny et al. [Ref 21] did not find strong abuse-liability ratings at either dose. The disconnect between controlled-study results and real-world abuse suggests that contextual factors, polydrug combinations, and individual differences (including CYP2C19 status) significantly shape the subjective experience.

---

## Safety & Toxicity

### Fatal Concentrations

From forensic postmortem studies [Ref 22] [Ref 24]:
- Blood carisoprodol **>15 mg/L** and liver concentration **>50 mg/kg** may be considered excessive and potentially fatal (McIntyre et al. 2012 [Ref 22]).
- In cases of **solo carisoprodol intoxication** (no other major contributing drugs): median blood concentration 36 mg/L (range 8–65 mg/L; n=5) [Ref 24] (Høiseth et al. 2007 [Ref 24]).
- Carisoprodol **can contribute to death even at therapeutic concentrations** when combined with other CNS depressants [Ref 22].
- Fatal toxicity index: **5.6–6.9 deaths per million defined daily doses (DDDs)** in Norway 1992–2003 [Ref 24].
- Carisoprodol and meprobamate show **low potential for postmortem redistribution** (central:peripheral blood ratio 1.31 ± 0.33; liver:peripheral 2.83 ± 1.51) [Ref 22], which facilitates more accurate forensic concentration interpretation.

### Polydrug Overdose Risk

- Concomitant use with opioids: adjusted HR **1.84 (95% CI, 1.34–2.54)** for opioid overdose (vs. opioids alone); risk increased with treatment duration >60 days, HR 1.80 [Ref 3] (Li et al. 2020 [Ref 3]).
- Confirmed in a separate cohort study with head-to-head SMR comparison [Ref 2] (Khan et al. 2022 [Ref 2]).
- The "Holy Trinity" (carisoprodol + opioid + benzodiazepine) carries the highest risk [Ref 6].
- **GHB + carisoprodol fatality** documented (combined CNS/respiratory depression with contraindicated use) [Ref 19].
- Sumatriptan polydrug fatality documented with carisoprodol 3.35 mg/L among multiple other drugs [Ref 33].

### Serious Adverse Events

- **Seizures**: Documented in withdrawal and in overdose; listed explicitly in DEA scheduling documentation as a consequence of misuse [Ref 4].
- **Serotonin syndrome**: Case series (Bramness et al. 2005 [Ref 27]) and recent case report (O'Flynn et al. 2025 [Ref 1]) document serotonin syndrome presentation. Mechanism unclear; may require distinct clinical management approach (cyproheptadine rather than standard GABAergic supportive care alone).
- **Respiratory depression**: Primary life-threatening mechanism, especially in polydrug context [Ref 6].
- **Psychomotor impairment**: Documented at therapeutic doses; significant DUI risk [Ref 21] [Ref 23].

### CYP2C19 Poor Metabolizer Risk

CYP2C19 poor metabolizers are at substantially elevated risk of toxicity. Poor metabolizer genotypes have been investigated specifically in **fatal carisoprodol intoxications** [Ref 16], suggesting a genetic contribution to fatal outcomes at otherwise standard doses.

### Elderly Population Risk

Carisoprodol appears on the **American Geriatrics Society Beers Criteria** as a potentially inappropriate medication for older adults due to CNS adverse effects and sedation risk (web-retrieved; not confirmed via primary literature API search — **flag for human review**).

---

## Harm Reduction

### Contraindications

Based on literature findings [Ref 32] [Ref 15]:
- **CYP2C19 poor metabolizers**: Standard doses produce ~4-fold higher exposure; caution required.
- **Concurrent opioids**: Substantially elevated overdose risk (HR 1.84) [Ref 3]; avoid co-prescription.
- **Concurrent benzodiazepines and alcohol**: Additive CNS depression; the "Holy Trinity" combination is particularly dangerous [Ref 6].
- **Duration >2–3 weeks**: Not recommended per FDA labeling; dependence risk increases substantially with prolonged use [Ref 32].
- **Elderly patients**: Not recommended (Beers Criteria — web-retrieved).
- **Pediatric use**: Not established for patients under 16 years [Ref 32].
- **Pregnancy**: FDA labeling notes decades of clinical use without identification of major birth defect risk, but formal safety studies are lacking [Ref 32].

### Drug Interactions — Critical Combinations

| Combination | Mechanism | Risk Level |
|---|---|---|
| Opioids | Additive respiratory depression; synergistic dopaminergic reward | Very high — HR 1.84 for overdose [Ref 3] |
| Benzodiazepines | Additive GABA-A potentiation, respiratory depression | Very high [Ref 6] |
| Alcohol | Additive CNS depression | High |
| GHB | Additive CNS/respiratory depression | High (fatality documented) |
| CYP2C19 inhibitors (e.g., omeprazole, fluoxetine) | Increased carisoprodol exposure | Moderate — increases toxicity risk |
| Serotonergic agents | Possible serotonin syndrome (mechanism unclear) | Moderate — case reports exist [Ref 27] [Ref 1] |

### Identification

Carisoprodol tablets are typically white and round; Soma 350mg tablets are a distinctive round white tablet. Street "red apple" formulations (carisoprodol combined with tapentadol) have been reported in UK harm reduction data [Ref 31]. Standard urine immunoassays do not typically screen specifically for carisoprodol; testing may require specific GC-MS panels.

---

## Tolerance & Dependence

### Tolerance Development

Tolerance to carisoprodol has been established in a **mouse model** via repeated administration [Ref 9] (Gatch et al. 2012 [Ref 9]). The same study demonstrated **precipitated withdrawal** using a GABA-A antagonist, confirming physical dependence develops. The mechanism is consistent with GABA-A receptor downregulation and subsensitivity, as seen with other GABA-A modulators (barbiturates, benzodiazepines).

### Dependence Liability

- Multiple case reports document physical and psychological dependence:
  - Meprobamate dependence developing from carisoprodol use [Ref 20] (Littrell et al. 1993 [Ref 20])
  - Classic carisoprodol abuse pattern [Ref 19] (Rust et al. 1993 [Ref 19])
  - Severe dependence after 14-year use with acute overdose [Ref 5] (Vo et al. 2017 [Ref 5])
  - Dependence in India (polydrug context) [Ref 21a]
  - North India abuse documentation [Ref 18] (Nebhinani et al. 2013 [Ref 18])
- The Norwegian prescription database showed 15% of patients received ≥75 defined daily doses in a single year (2004), indicating a substantial proportion developing high-use patterns consistent with tolerance and dependence [Ref 12] (Bramness et al. 2007 [Ref 12]).
- High use of carisoprodol was strongly associated with high concurrent use of benzodiazepines and opioids [Ref 12].

### Withdrawal Syndrome

- Withdrawal symptoms (from case reports and clinical literature) include: anxiety, insomnia, restlessness, craving, headache.
- Abrupt cessation after prolonged high-dose use can produce severe withdrawal including: **seizures, delusions, hallucinations** [Ref 4] [Ref 5].
- Standard management: benzodiazepines (first-line) or antipsychotics [Ref 5].
- Severe cases may be resistant to standard treatment [Ref 5].
- Withdrawal is clinically similar to barbiturate/benzodiazepine withdrawal; life-threatening in severe cases.

### Cross-Tolerance

No published human data on cross-tolerance with other GABAergic agents specifically for carisoprodol. By class analogy with barbiturates, cross-tolerance with benzodiazepines, alcohol, and barbiturates is expected, but this has not been formally demonstrated in humans. **Flag for editorial attention.**

---

## Interactions

### CNS Depressants

All CNS depressants carry additive risk when combined with carisoprodol. The highest-risk combinations are:

1. **Opioids**: HR 1.84 for opioid overdose [Ref 3]; synergistic respiratory depression via distinct but co-expressed μ-opioid and GABA-A receptor mechanisms [Ref 6]. Risk increases with duration of combined use.
2. **Benzodiazepines**: Additive GABA-A-mediated respiratory depression; "Holy Trinity" combination documented as a specific high-risk pattern [Ref 6].
3. **Alcohol**: Additive CNS depression; commonly encountered in overdose cases.

### Serotonergic Agents

Case series data [Ref 27] and a 2025 case report [Ref 1] document serotonin syndrome in the setting of carisoprodol use. The mechanism is uncharacterized. Caution with SSRIs, SNRIs, MAOIs, tramadol, and triptans is warranted. The combination of sumatriptan and carisoprodol has been documented in a fatal multidrug case [Ref 33].

### CYP2C19-Mediated Interactions

- **Inhibitors** (e.g., omeprazole, esomeprazole, fluoxetine, fluvoxamine, ticlopidine): Decrease CYP2C19 activity → increased carisoprodol levels, decreased meprobamate levels.
- **Inducers** (e.g., rifampin, carbamazepine, St. John's Wort): Increase CYP2C19 activity → decreased carisoprodol exposure.
- FDA advises caution and dose adjustment consideration [Ref 32] [Ref 15].

---

## Legal Status

| Jurisdiction | Status | Date/Notes |
|---|---|---|
| **United States** | Schedule IV (Controlled Substances Act) | DEA final rule December 12, 2011; effective January 11, 2012 [Ref 30] |
| **European Union** | Marketing authorization withdrawn | 2008 [Ref 23] |
| **Norway** | Highest scheduling; withdrawn from market | Rescheduled August 1, 2007; market withdrawal May 1, 2008 [Ref 23] |
| **United Kingdom** | Not currently controlled under MDA 1971; ACMD recommending Class C, Schedule 4 | ACMD report 2025 [Ref 31]; UN Convention Schedule IV (CND Decision 68/6, 2025) creates international obligation |
| **Canada** | Removed from Prescription Drug List; reclassified Schedule V controlled substance | As of April 14, 2025 [web-retrieved] |
| **Australia** | Not on Australian Register of Therapeutic Goods | Can be accessed via Special Access Scheme [web-retrieved] |
| **South Korea** | Controlled | Following documented abuse and fatalities; implemented controls [Ref 26b — PMID 21338024] |
| **International** | UN Convention on Psychotropic Substances Schedule IV | CND Decision 68/6, 2025 [Ref 31] |

*Note:* Sweden withdrew carisoprodol from the market in 1994 (web-retrieved; not API-verified — flag). India: remains available in some states; documented abuse [Ref 18]. The drug was deliberately designed to be less addictive than meprobamate [Ref 28] but has proven to have significant abuse potential, triggering progressive international regulatory action over 60+ years.

---

## Clinical Trials

**Completed Phase III trials** (ClinicalTrials.gov):

- **NCT00671879**: "Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back." Status: COMPLETED. Phase III. Sponsor: Meda Pharmaceuticals. Condition: Lower Back Pain.
- **NCT00671502**: "A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back." Status: COMPLETED. Phase III. Sponsor: Meda Pharmaceuticals. Condition: Lower Back Pain.

**Withdrawn trial:**
- **NCT03508167**: "Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain." Status: WITHDRAWN. Phase III. Sponsor: Ache Laboratorios Farmaceuticos S.A. (Brazil).

**Published placebo-controlled trial:**
- Ralph et al. (2008) [Ref 25]: Double-blind, placebo-controlled RCT of carisoprodol 250mg TID+QHS for acute lower-back spasm.

**Systematic review evidence:**
- Chou et al. (2004) [Ref 10]: Systematic review (101 RCTs); "fair evidence" that carisoprodol is effective compared to placebo in patients with musculoskeletal conditions (primarily acute back/neck pain).
- van Tulder et al. (2003) [Ref 11]: Cochrane review; strong evidence for muscle relaxants > placebo for acute LBP; adverse events (especially CNS effects) significantly more prevalent with muscle relaxants.

No active recruiting trials for carisoprodol were identified on ClinicalTrials.gov as of this research date. Given the drug's scheduled status and international withdrawal, new clinical development is unlikely.

---

## Community Feedback Analysis

No community feedback submitted. (Part A2 of the brief was empty.)

---

## Gaps & Flags

### Unverified / Missing Data

1. **SMILES string**: Not returned by PubChem API in this query. CCC(C)(COC(N)=O)COC(=O)NC(C)C is widely cited (web-retrieved) but should be confirmed via PubChem directly. **Flag for verification.**
2. **CAS number**: 78-44-4 is widely cited but was not returned via PubChem API. **Flag for verification.**
3. **LD50**: No LD50 in humans is published. Animal LD50 data not identified in PubMed searches. **Flag as gap.** The seed data notes "potentially lethal when mixed with depressants" but no specific LD50 value should be asserted.
4. **Absolute bioavailability**: Formally not established per FDA prescribing information. **Flag as gap.**
5. **Protein binding and volume of distribution**: Not provided in FDA label; not found in PubMed searches. **Flag as gap.**
6. **Physical properties** (melting point, solubility): Not confirmed via published primary literature in this search. Web-retrieved sources indicate ~92–94°C melting point and poor water solubility — **flag for human review.**
7. **Specific receptor binding affinity values (Ki/EC50)**: No Ki or EC50 values at specific GABA-A subunit configurations were extractable from abstracts. Full-text access to Kumar et al. 2015/2017 would be needed for specific quantitative binding data.
8. **Cross-tolerance with other GABAergic agents**: Not published in humans. Class-inference only.
9. **Serotonergic mechanism**: Uncharacterized. No binding affinity data at serotonin receptors found. The serotonergic cases could represent an unidentified pharmacological mechanism or pharmacokinetic drug interaction. **Safety-critical gap.**
10. **Sweden withdrawal (1994)**: Web-retrieved; not confirmed via primary literature.
11. **Beers Criteria explicit listing**: Web-retrieved; not confirmed via the primary published Beers Criteria document in this search.

### Contradictions Between Sources

1. **Mechanism characterization**: The brief describes carisoprodol as a "GABA-A receptor positive allosteric modulator" — this is accurate but incomplete; carisoprodol is also a **direct agonist** (direct gating agonist) at GABA-A, not merely a PAM. The generation agent should ensure this distinction is reflected.
2. **Serotonergic activity vs. pure GABAergic mechanism**: Multiple sources [Ref 1] [Ref 27] document presentations inconsistent with a purely GABAergic mechanism, suggesting additional serotonergic activity. The seed data does not mention this. This is not a simple discrepancy but a genuine scientific debate.
3. **Abuse potential**: The drug was designed to have *less* abuse potential than meprobamate [Ref 28], yet it has demonstrated substantial abuse potential in practice. The brief's characterization is accurate for the current state; the historical intent is contextually important.

### Safety-Critical Flags for Human Review

- **FLAG**: Fatal blood concentration threshold of >15 mg/L (potentially lethal alone) and lower when combined with other depressants — this value is not from a single definitive study but represents synthesis across multiple forensic case series.
- **FLAG**: Serotonin syndrome mechanism is unresolved. Treatment approach may differ from standard carisoprodol overdose management. Clinical editorial review recommended.
- **FLAG**: CYP2C19 poor metabolizer populations (especially Asian populations at 15–20%) face substantially elevated risk at standard therapeutic doses. This should be prominently flagged in harm reduction content.
- **FLAG**: The combination of carisoprodol + opioids is not explicitly contraindicated in the FDA label per se, but population-based data show HR 1.84 for overdose — editors should ensure this is clearly communicated.
- **FLAG**: UK status is currently in transition (not controlled → ACMD recommendation for Class C → UN obligation). Legal status content will need updating as domestic UK legislation is enacted.